# Redlands Health — Strategic Analysis & Growth Blueprint

### An independent strategic assessment of Redlands Community Hospital and the path to an integrated, prevention-first regional health system

**Prepared as a consulting-style engagement | Inland Empire, California | 2026**

> *Planning analysis built on public/official data (CMS, HCAI, IRS 990, DOL Form 5500, CMS NPPES, City of Redlands ACFR). Figures marked as estimates are modeled planning figures, not actuarial or audited.*

---

## Table of Contents

1. [Executive Summary](#executive-summary)
2. [Workstream 1 — Macro-Environment & Future Trends (PESTEL/STEEP)](#1-macro-environment--future-trends-pestelsteep)
3. [Industry Structure: Porter's Five Forces — Redlands / Inland Empire](#2-industry-structure-porters-five-forces--redlands--inland-empire)
4. [Market Demand, Leakage & Trend Analysis](#3-market-demand-leakage--trend-analysis)
5. [Internal Capability, Value Chain & Financial Diagnostic](#4-internal-capability-value-chain--financial-diagnostic)
6. [Payer, Employer, Covered-Lives & Physician-Supply](#5-payer-employer-covered-lives--physician-supply)
   - [5A. Resident vs. Commuter Market Read — Network Efficiency by Residence](#5a-resident-vs-commuter-market-read--network-efficiency-by-residence)
7. [Regulatory & Deal-Structure Navigation](#6-regulatory--deal-structure-navigation-the-compliant-path-through-californias-waters)
8. [SWOT → TOWS: "Redlands Health" Vertical-Integration Strategy](#7-swot--tows-redlands-health-vertical-integration-strategy)
9. [Strategic Options, Market Entry & Growth Horizons](#8-strategic-options-market-entry--growth-horizons)
9b. [8A. Acute Service-Line Market Entry & Reclaim Roadmap](#8a-acute-service-line-market-entry--reclaim-roadmap)
10. [Financial & Value-Creation Case](#9-financial--value-creation-case)
11. [Recommendations & Roadmap](#10-recommendations--roadmap)
12. [Appendix A — Partner Review (How the Strategy Was Stress-Tested)](#appendix-a--partner-review-how-the-strategy-was-stress-tested)
13. [Appendix B — Data Sources & Method](#appendix-b--data-sources--method)

---

## Executive Summary

**The situation is urgent, and the evidence is unambiguous.** Redlands Community Hospital (RCH) is an independent, 211-bed non-profit losing money on a shrinking core: an ~$8.6M operating loss in FY2024 (-2.1% margin), inpatient discharges down 31% since 2018, births down 38%, and net assets drawn down 28% from a 2017 peak. Meanwhile the hospital wins the front door it has — roughly 57-59% ED share in its home ZIPs — but loses the patient it should keep: in its five-ZIP core draw area RCH retains only **36.9% of inpatient discharges (15,429 total; 5,692 RCH)**, leaking ~63% [rch_market_share_leakage.csv]. The strategic logic of "Redlands Health" — evolve from a standalone acute hospital into a vertically integrated, prevention-first regional system — is sound and internally justified: RCH's value chain leaks at precisely the pre-service and after-service layers the vision targets, and the do-nothing trajectory (~-6%/yr discharge decay) erases the base.

**But our own review forced us to rebuild the demand and finance case, and the honest numbers are smaller than the first draft claimed.** Three corrections matter for the board:

1. **The recapturable leak is ~2,500-3,100 discharges, not ~5,100.** Re-running the source CSV, structurally-locked volume (Kaiser closed-network ~1,857 + LLU Children's, Arrowhead, and LLU Med Center tertiary/trauma/peds ~5,027) is roughly **70% of the leak**, not 48%. The credible near-term target is lifting core share from 36.9% to **40-42%**, worth +480 to +788 incremental discharges — and we report this in **contribution margin (~+$2-5.5M), not the ~$14M gross-revenue figure**, because recaptured volume is Medi-Cal-skewed and the original number double-counted ASC revenue.

2. **The ED "conversion gap" is largely a mirage.** RCH already admits ~5,625 ED patients — about 58.6% of all its discharges already flow through the ED. The 10.1% admit-to-visit ratio is a normal treat-and-release pattern, not an 18-point recoverable gap. The real, defensible lever is **transfer-prevention and downstream referral capture** (keeping community-acuity admissions and their families in-system) — and its dollars must NOT be stacked on the share-recapture dollars.

3. **The balance sheet is weaker than "51 days" implies.** That figure is net assets (equity) over daily opex — not cash. True unrestricted days-cash-on-hand is materially lower once PP&E and restricted/donor funds are excluded. **The program cannot be balance-sheet-funded.** External capital — a risk-enablement JV/managed-services partner and/or a philanthropic campaign — is a precondition of program start, not a fallback.

**What survives the scrutiny is the strategy's spine.** Forward integration is the only adaptive path that stops the leak, monetizes the Inland Empire's elevated chronic-disease burden (SB County diabetes 17.0%, HTN 30.2%, obesity 36.5%), and counters payer-owned Optum/Beaver's referral gatekeeping that California's Corporate Practice of Medicine bar prevents RCH from out-employing. The entry vehicle is correct: **cooperation-before-purchase** — aggregate the ~320 independent corridor physicians (anchors CAMG, founded 2024 to keep care local, and a now-independent RYMG) into an RCH-led CIN via affiliation/MSO, with zero Knox-Keene license and sub-CMIR staging. The competitive posture is correct: **focused differentiation** — concede trauma/peds/quaternary to Loma Linda and Arrowhead, and win on local, integrated, lower-total-cost community care across the Redlands → Yucaipa → San Gorgonio Pass arc.

**The decisive risk the first draft buried is execution.** A money-losing, sub-scale hospital with an incoming CEO, no VBC competency, and a live CMS 2-star rating cannot stand up a CIN, MSO, ASC program, friendly-PC, and at-risk contracting function concurrently. We therefore recommend: **green-light Horizon 1 only**; make a funded organizational-readiness workstream (named CEO sponsor + guiding coalition + hired VP Population Health/CIN ED, ideally via a turnkey risk-enablement partner) a hard gate; make the **Phase 0 quality fix** (re-enter Leapfrog, remediate stroke mortality, reconcile the 2-star-live vs. 4-star-marketed claim) a stop/go test of whether the organization can execute at all; and treat the §1206(l) foundation, global-risk Knox-Keene, and an owned health plan as **conditional options earned later — not a committed roadmap**. CIN shared savings should be modeled with a 3-5 year J-curve (~$0 in years 1-3), and the day-one VBC slice (low single-digit thousands of lives) must be kept distinct from the 80-150k aggregation ceiling that is already attributed to incumbent payers.

Done this way, Redlands Health is a defensible, capital-light, defense-and-growth program. Done the way the first draft implied — all horizons committed, gross revenue counted as cash, balance sheet funding a go-it-alone — it is the most common way transformations like this fail.

### Headline thesis

Redlands Community Hospital owns two genuinely defensible assets — a dominant ED front door (~57-59% home-ZIP share on 61,472 visits) and a VRIO ortho/spine franchise — but leaks value at exactly the two ends a prevention-first system must own: pre-service primary care and after-service population health. With discharges down 31% (13,946 to 9,604, 2018-2024), an ~$8.6M FY2024 operating loss, and 63% of core-market inpatients leaking out, standing still is the value-destructive option, not the safe one. The right strategy is therefore forward vertical integration by cooperation-before-purchase — aggregate the corridor's ~320 independent physicians into an RCH-led clinically integrated network, convert ED loyalty into retained community-acuity admissions, and grow ambulatory/ASC capacity where demand is actually migrating — executed at the lowest compliant regulatory rung. But the binding constraint is not market size or even capital; it is change capacity and management bandwidth at a money-losing, sub-scale hospital with a new CEO (Jan 2026) and no population-health muscle. So the program must be green-lit only as Horizon 1 (CIN + transfer-prevention + direct-to-employer + a hard quality fix), with the foundation, Knox-Keene risk-bearing, and owned-plan endgame treated as conditional options to be earned — gated behind external/partner capital and a funded organizational-readiness workstream, not committed on day one.

### Big moves

- **Phase 0 — Fix the quality-credibility gap as a stop/go gate, not a parallel task** (H1 — 0-12 months (2026)) — Live CMS 2/5 stars while marketing 4/5, stroke 30-day mortality 'Worse than national,' and Leapfrog non-participation since Fall 2024 price every CIN-recruitment, payer, and employer conversation at a discount. Re-entering Leapfrog, remediating stroke mortality, and reconciling the marketing claim is the cheapest, most controllable early win — and success or failure here is the truest test of whether the organization can execute the harder steps that follow.
- **Stand up the organizational-readiness workstream and lock external/partner capital BEFORE any deal** (H1 — 0-12 months (2026)) — The binding constraint is management bandwidth, not market size. Secure the incoming CEO's committed sponsorship and a named guiding coalition (Kotter); hire a VP Population Health/VBC and a CIN executive director as funded line items; and strongly favor a turnkey risk-enablement / managed-services partner that brings the CIN/MSO/care-management platform — converting an execution-capacity problem into a partnering decision. Make this capital and these hires a precondition of program start.
- **Form the RCH-led CIN by cooperation — sign CAMG and RYMG, build real clinical+financial integration before any joint contracting** (H1 — 0-24 months (2026-2027)) — Aggregating the ~320 independent corridor PCPs neutralizes RCH's #1 binding force (payer-owned Optum supplier power) that CPOM bars RCH from out-employing. CAMG (founded 2024 to stay local) and a now-independent RYMG are ideologically aligned. Critically, build shared EHR/care-pathways/shared-risk FIRST — joint payer negotiation without genuine integration is per-se price-fixing. Model the lives base WITHOUT RYMG to prove the program survives if the key anchor walks.
- **Convert ED loyalty into retained community-acuity admissions via transfer-prevention (not a phantom 18-point conversion gap)** (H1 — 0-24 months (2026-2027)) — RCH already admits ~58.6% of its discharges through the ED, so the lever is keeping community-acuity patients who currently get transferred — backed by hospitalist/specialist on-call depth and care coordination — and capturing their downstream families into the CIN. This supports the realistic 40-42% core-share target (+480 to +788 discharges) with zero bed capex at 56.6% occupancy. Do not book ED dollars on top of share-recapture dollars.
- **Launch rung-1 direct-to-employer contracts and grow ambulatory/ASC capacity where demand is migrating** (H1-H2 — 0-36 months (2026-2028)) — Direct-contract ESRI (self-funded, Cigna-ASO, 4,890 participants) and RUSD, and convert RCH's own 1,405-life plan into a proof-of-concept — banking commercial lives with zero licensure. Redirect capital to ASCs/RPM/hospital-at-home (outpatient surgery 3,871 already exceeds inpatient 2,854; outpatient is 58% of net patient revenue) rather than beds — also sidestepping the 2030 seismic-capex trap. Present 22,000 capturable lives as TAM with a conversion funnel to a few thousand year-1-3 wins.
- **Make an explicit OB and med-surg portfolio decision, and execute Pass-corridor market development** (H2 — 12-48 months (2027-2030)) — Births are down 38% to 1,336 — sub-scale for a fixed-cost unit. Decide deliberately: defend OB as a community-anchor maternity first-touch that feeds family commercial lives into the CIN, or harvest it — but a botched closure poisons the 'keep care local' brand the whole pitch depends on. In H2, develop ambulatory/urgent-care access across Yucaipa→Calimesa→Beaumont/Banning, where RCH is already the #1 ED and IP feeder (Yucaipa 92399, 39.9% IP share) and the Pass is served only by one fragile 79-bed district hospital.
- **Treat the §1206(l) foundation, global-risk Knox-Keene, and an owned health plan as conditional options earned later — not a committed endgame** (H3 — 60-120 months (2031-2035), conditional) — The §1206(l) bar (40+ MDs, 10+ specialties, 2/3 full-time, plus a standing research/education mission) is in direct tension with the independence pitch used to recruit the physicians — realistically a year-7+ proposition that may never close. The durable operating model is the friendly-PC + MSO, which is CPOM-compliant and preserves the 'stay independent' promise. A full Knox-Keene owned plan is a category change in risk and capital that routinely sinks well-funded systems; label it a remote option requiring a separate future board decision, and bear global risk only after the CIN has demonstrably managed medical cost for multiple years, inheriting RBO infrastructure from aggregated IPAs.

---

# 1. Macro-Environment & Future Trends (PESTEL/STEEP)

## Workstream 1 — Macro-Environment & Future Trends (PESTEL/STEEP)

Applying Ginter et al. (7e) Ch. 2 general-environment process — *scanning → monitoring → forecasting → assessing* — to the Inland Empire (IE) health market over a 3–7 year horizon (2026–2032). For each STEEP/PESTEL force: current state → trend → "so what for Redlands Health." All Redlands-specific figures are sourced to the project data files; California regulatory citations are to source-of-truth statutes.

### P — Political / Regulatory

| Driver | Current state (2026) | 3–7 yr trend | So-what for Redlands Health |
|---|---|---|---|
| **CalAIM / DHCS population-health** | Medi-Cal is mid-build on ECM and Community Supports; IE plans (IEHP, Molina) dominate. Largest independent Medi-Cal IPA in-corridor (Inland Faculty Medical Group, 230K+ IEHP-Molina lives) is **Optum/NAMM-owned** (`independent_provider_analysis.md`). | CalAIM matures into standing at-risk, justice-involved and SDOH-funded population-health infrastructure; ECM/Community Supports become permanent. | The CalAIM rails *are* the prevention-first thesis pre-funded by the state. RCH's independent-IPA targets (All United, MedEx, SoCalHealth, LaSalle slice) already carry IEHP-Medi-Cal capitation — they bring **attribution and infrastructure, not just bodies**. |
| **OHCA cost-growth + AB1415 transaction review** | OHCA cost target ~3.5% trending toward ~3.0%; **AB1415 (eff. 1/1/2026)** requires **90-day notice + possible CMIR** on material-change deals closing on/after 4/2/2026 (`california_regulatory_requirements.md`). | OHCA tightens targets; CMIR delays/conditions become a routine gate on affiliations and MSO deals. | Every CIN affiliation, foundation stand-up, or acquisition must be **sequenced around a 90-day OHCA clock**. Build organically and via friendly-PC/MSO first; reserve notice-triggering M&A for later waves. |
| **SB351 CPOM codification** | Signed 10/6/2025, eff. 1/1/2026; codifies CPOM, restricts **PE/hedge-fund** clinical control — but **explicitly EXCLUDES hospitals and public agencies** (`california_regulatory_requirements.md`). | PE-backed roll-ups (Optum's model) face tightening noncompete/clinical-control limits; NFP hospitals do not. | A **structural advantage**: SB351 constrains RCH's payer-owned rival while leaving RCH free to use a 1206(l) foundation or friendly-PC+MSO. Frame CIN recruitment as "stay independent, stay local" against Optum consolidation. |
| **Medicare Advantage growth + CMS V28** | MA penetration high and rising in CA; CMS V28 risk-model phase-in (2024–2026) compresses risk-score revenue. | MA share keeps climbing; V28 fully phased; accurate HCC capture and care management become the margin determinant. | The aging Yucaipa/Calimesa/Beaumont senior panels (e.g., Premier Senior Medical Group) are the MA/ACO risk-contract prize — but only a clinically integrated, documentation-disciplined network monetizes them under V28. |
| **Site-neutral payment + 340B** | Medicare site-neutral pressure on HOPD rates; ongoing 340B contraction risk. | Site-neutral expansion erodes the hospital-outpatient premium; 340B savings stay under threat. | Reinforces, not contradicts, the strategy: shift electives to **owned ASCs** (lower cost basis) and build a primary-care/CIN moat that doesn't depend on the HOPD rate differential. |
| **No Surprises Act / price transparency** | NSA + transparency rules live; consumer price-shopping rising. | Transparency-driven steerage and direct-to-employer contracting accelerate. | Enables the **self-funded-employer direct-contract wedge** — 12 in-city / 64 wider self-funded employers (`health_plans_form5500.md`) RCH can approach with a transparent, lower-total-cost integrated network. |

### E — Economic

**Current state.** RCH posted **FY2024 revenue ~$407.1M against expenses ~$415.7M — an ~$8.6M operating loss** (`rch_hospital_data.md`, IRS 990), the latest in a string of thin/negative operating years rescued by non-operating gains. Net outpatient revenue ($232.5M) already exceeds net inpatient ($167.6M) — the business has *already* tilted ambulatory. The IE economy is a logistics/warehouse engine: RCH is the **3rd-largest city employer (1,847)** behind Redlands USD and ESRI, with Amazon and Burlington DCs among the top area employers (`redlands_top_employers.md`), implying a high commercial-but-modest-wage, increasingly Medi-Cal-and-Medicare payer mix.

**3–7 yr trend.** IE population and job growth continues to outpace coastal California, but the job base (logistics, retail) skews payer mix toward Medi-Cal/exchange; wage and labor-cost inflation, capital cost, and seismic-retrofit capex (below) keep hospital operating margins compressed sector-wide.

**So-what.** A standalone acute hospital cannot margin its way out on inpatient volume that fell from **13,946 discharges (2018) to 9,604 (2024)** with ALOS rising 3.5→4.5 days (`rch_hospital_data.md`). The economically rational path is to **capture the leaked commercial life and the value-based dollar**: in the core draw area RCH holds only **36.8% inpatient share (63.2% leakage)**, ~28% of it to the Loma Linda system and ~11% structurally locked in Kaiser (`rch_market_leakage_analysis.md`). Recapturing even a fraction of leaked commercial inpatient days plus owning the primary-care front door is the only durable margin engine.

### S — Social / Demographic

| Indicator | Figure | Source | Implication |
|---|---|---|---|
| San Bernardino Co. diabetes | **17.0%** (highest among neighbors) | `independent_provider_analysis.md` | Chronic-disease density = the value-based prize: the ~5% high-risk tier drives ~50% of cost. |
| Hypertension | **30.2%** (2023) | same | Population-health management has unusually high ROI here. |
| Obesity | **36.5%** (2024) | same | Prevention-first programming maps to community-benefit obligations (H&S §127340). |
| Pass-corridor growth | Beaumont/Banning/Calimesa fastest-growing, thin on independent PC | same | The **clearest geographic growth lane** before LLU/Kaiser entrench. |
| Aging Yucaipa/Calimesa | Senior-heavy, under-consolidated panels | same | High-value MA/ACO risk panels; Yucaipa 92399 is RCH's **#1 inpatient feeder (19.8%)** and #1 ED ZIP. |

**Trend.** IE and San Gorgonio Pass population grows and ages over the horizon; chronic-disease burden stays above the California average; healthcare consumerism rises (price/quality shopping, demand for local access). **So-what:** demographics *supply the covered lives and the medical-loss-ratio upside* the strategy needs — but RCH must convert its strong front-door franchise (ED share ~57–59% in home ZIPs; falling births 2,161→1,336) into managed, attributed primary-care relationships before Optum/LLU lock them.

### T — Technological

**Current state & trend (2026→2032).** (1) **Ambient AI clinical documentation** moves from pilot to standard, easing the PCP-capacity constraint that gates the CIN. (2) **Hospital-at-home + remote patient monitoring** mature into reimbursed modalities — directly enabling at-risk management of the ~24k–44k high-utilizers in the manageable-lives model. (3) **Surgical migration to ASCs** accelerates: RCH already shows outpatient surgeries **rising 3,299→3,871** while inpatient surgeries **fall 3,066→2,854** (`rch_hospital_data.md`) — the trend is in the data, not hypothetical. (4) **Telehealth, genomics, and EHR interoperability** lower the cost of a distributed, prevention-first network.

**So-what.** Technology is a **tailwind that de-risks the two hardest constraints** — physician supply (ambient AI) and capital-heavy bed expansion (ASC + home shift). RCH's ~56.6% GAC occupancy gives bed headroom, but the smart capital goes to ASCs, RPM, and the digital CIN backbone, not inpatient towers.

### E — Environmental

**Current state & trend.** Wildfire smoke, extreme heat, and degraded IE air quality (among the worst U.S. basins) drive **respiratory and cardiac demand** — structurally supportive of RCH's rising ED volume (38,904→55,847 visits, 2018→2024). Climate resilience and **HCAI seismic mandates (SPC deadlines toward 2030)** impose mandatory capital (`california_regulatory_requirements.md`). **So-what:** climate-driven acute demand is a (grim) volume tailwind for the ED franchise and a reason to invest in chronic-respiratory/cardiac population management; the seismic capex is a **forcing function** to rationalize the physical plant toward ambulatory/ASC rather than over-investing in retrofit of low-occupancy med-surg beds.

### L — Legal

The legal regime is the binding constraint and is detailed in Workstream-level regulatory analysis; the macro read: **CPOM (B&P §2400)** bars direct physician employment → RCH must use a **1206(l) foundation** (40+ MDs, 10+ specialties) or **friendly-PC+MSO**; **Knox-Keene** governs any risk-bearing (shared-savings = no license; global risk = Restricted KK; own-the-plan = full KK + reserves); **FTC/DOJ** require genuine clinical + financial integration before a CIN may jointly negotiate; **AG review (Corp Code §5914–5925)** gates NFP asset transfers. **So-what:** the legal map dictates *sequencing* — contract/CIN first (no license), shared savings, then graduated risk — and SB351's hospital exclusion is a rare legal edge.

### The 3–4 macro forces that most reshape the opportunity

1. **CalAIM + payer-mix shift to Medi-Cal/Medicare with rising MA (V28)** — makes at-risk, prevention-first primary care the *only* durable margin engine, and the state pre-funds the rails.
2. **The 2026 California regulatory transition (OHCA/AB1415 + SB351)** — simultaneously gates RCH's M&A timing (90-day clock) and *advantages* it (hospital exclusion from PE restrictions) versus Optum.
3. **Technological migration to ambulatory/ASC/home + ambient-AI** — relaxes RCH's two hardest constraints (capital and physician supply) and is already visible in RCH's own surgery mix.
4. **IE demographic growth + elevated chronic-disease burden** — supplies the capturable covered lives and the medical-loss-ratio upside that monetize integration.

---

# 2. Industry Structure: Porter's Five Forces — Redlands / Inland Empire

## Industry Structure: Porter's Five Forces — Redlands / Inland Empire

Porter's Five Forces (Ginter et al., 7e, Ch. 3, *industry and competitive analysis*) explains why an industry is or is not profitable and where a single competitor can defend a position. For Redlands Community Hospital (RCH), the answer is blunt: this is a low-attractiveness industry segment for a standalone independent. Four of five forces rate Medium-High or High. The exercise's value is not the scorecard but the diagnosis of *which* forces bind and *where* the structural seams are.

### Force ratings at a glance

| Force | Rating | One-line basis (Redlands-specific) |
|---|---|---|
| **Rivalry among competitors** | **HIGH** | RCH = 211 beds vs. ~2,944 system beds nearby; keeps only 36.8% of its own core market |
| **Supplier power (physicians/labor)** | **HIGH** | Optum/Beaver (UnitedHealth-owned) is largest group + #4 employer; CPOM bars RCH from employing MDs |
| **Buyer power (payers/employers)** | **MEDIUM-HIGH** | Concentrated Medi-Cal MCOs (IEHP/Molina); payer-owned group steers referrals; price transparency |
| **Threat of substitutes** | **MEDIUM-HIGH** | ASCs (3 within blocks), telehealth, urgent care, DPC, hospital-at-home erode HOPD/IP margin |
| **Threat of new entrants** | **MEDIUM** | High capital + CON-like barriers for hospitals, but low for ASC/retail/FQHC adjacencies |

### Rivalry — HIGH

RCH is a small independent surrounded by three large systems and a county safety-net hospital. Within the bed set of the immediate competitive ring, **RCH holds only ~6.7% of beds** (211 of 3,155: LLU system 1,024 across five campuses, Kaiser IE 775, Dignity 689, Arrowhead 456) (*competitors.md; hcai_utilization_comparison.csv*). Scale rivalry is unwinnable head-to-head.

The sharper signal is share inside RCH's *own* home market. In the core draw area (Redlands/Yucaipa/Mentone/Calimesa) RCH captures **36.8% of inpatient discharges (63.2% leakage)**, while the **Loma Linda system pulls ~28%** of that same core and **Kaiser Fontana ~11%** (*rch_market_leakage_analysis.md*). RCH leads its core by only **8.4 points over the LLU system** — a fragile lead in the hospital's back yard.

| Rival | Beds | Trauma | GAC occ. | Basis of competition vs. RCH |
|---|---:|---|---:|---|
| **Loma Linda Univ. Health** | 409 (+364 peds, +5 campuses) | Level I | 109% | Academic acuity, trauma/peds monopoly, faculty group; expanding *into* Redlands |
| **Kaiser Permanente (IE)** | 775 (3 hosp) | None | ~50% | Closed network — removes lives from the market entirely |
| **Dignity/CommonSpirit** | 689 (2 hosp) | None | 37-61% | National-system scale, contracting leverage, capital |
| **Arrowhead Regional** | 456 | Level I | 86% | County safety-net magnet for trauma + unfunded |
| **San Gorgonio Memorial** | 79 | None | 27.5% | District hospital, financially fragile; the *only* ER in the Pass |
| **RCH (us)** | 211 | None | 56.6% | Cost/access/experience differentiation; ortho-spine strength |

The basis of competition is differentiated by acuity tier, not price: LLU and Arrowhead own tertiary/quaternary and trauma (the two run hottest at 86-109% occupancy, the two Level I centers); RCH competes in community-acuity med-surg, ED, OB, and elective ortho. Critically, **rivalry intensity is asymmetric** — LLU is *expanding into Redlands proper* (Surgical Hospital 28 beds, Behavioral Medicine 89 beds, urgent care), so the rivalry is escalating, not stable (*competitors.md*).

### Supplier power — HIGH (most-binding force #1)

The binding supplier is not labor or devices — it is **physician control**, and it is structurally rigged against RCH on two axes.

First, **Optum/Beaver Medical Group is owned by UnitedHealth, a payer**, operates ~11 corridor offices, and is the city's **#4 employer (~1,000)**. As a risk-bearing, payer-aligned group it controls **primary-care attribution and downstream referral steering** — it can direct admissions and outpatient volume toward or away from RCH (*competitors.md*). A standalone hospital whose feeder physicians are owned by a national payer-provider has, in Porter's terms, a supplier that can forward-integrate and capture the hospital's margin.

Second, **California's Corporate Practice of Medicine bar (B&P §2400) prevents RCH — a private NFP community hospital — from directly employing physicians** to counter this. The compliant workarounds are deliberately high-bar: a 1206(l) medical foundation (40+ MDs, 10+ specialties, 2/3 full-time, research/education mission) or a friendly-PC + MSO (*california_regulatory_requirements.md*). This converts physician supply into the *gating constraint* of the entire strategy: network adequacy itself is enforced at 1 PCP per 2,000 enrollees, so RCH cannot bear risk without securing physicians it cannot legally employ outright.

Nursing/clinical labor (CA-mandated ratios, statewide shortage) and IT/device vendors add a Medium overlay, but the decisive supplier lever is the physician base.

### Buyer power — MEDIUM-HIGH

RCH's buyers are payers and employers, and they are concentrated. **Medi-Cal managed care (IEHP, Molina)** dominates the IE's payer mix and sets near-administered rates — high buyer power on a large volume share. On the commercial side, the open networks (Anthem/UHC/Blue Shield/Aetna/Cigna) negotiate against a sub-scale independent that cannot match Dignity's or Kaiser's system leverage. **Price transparency** (CMS machine-readable files) further commoditizes shoppable services. The compounding factor unique to Redlands: the largest physician buyer-of-referrals (Optum/Beaver) is itself payer-owned, so buyer power and supplier power *reinforce* each other through the same UnitedHealth entity. The offsetting wedge is the **self-funded employer** (12 in-city / 64 wider) who can be approached for direct contracts — buyer power flips toward RCH only when RCH brings a differentiated, lower-total-cost network the employer cannot get from a closed Kaiser or a high-cost academic system.

### Threat of substitutes — MEDIUM-HIGH

Substitution is actively eroding RCH's two volume engines. RCH's own data shows **inpatient discharges falling 13,946 → 9,604 (2018-2024) while ED visits rose to 55,847** and **outpatient surgeries climbed to 3,871 as inpatient surgeries fell to 2,854** — the textbook migration to lower-cost sites of care. RCH already runs **58% of its surgeries outpatient**, and **three ASCs sit within blocks** capturing elective ortho/GI/pain at lower cost (*competitors.md; hcai_utilization_comparison.csv*). Telehealth, urgent care, direct primary care, and hospital-at-home each substitute for an ED visit or an inpatient day. Substitutes threaten margin, but they are also *ownable* — an RCH ASC and access strategy turns a substitution threat into a captured channel.

### Threat of new entrants — MEDIUM

For a full-service hospital, entry barriers are high (capital, seismic/HCAI plan review, CDPH licensure, AG review of NFP transfers, and now OHCA/AB1415 90-day notice + Cost & Market Impact Review on material changes, effective 1/1/2026). But entry into RCH's *adjacencies* is cheap and happening: Kaiser continues organic expansion; ASCs proliferate; CVS/Amazon/Optum retail and virtual-first clinics enter primary care; and FQHC expansion is real — **Neighborhood Healthcare opened a Beaumont site (Dec 2024, ~8,000 patients)** in RCH's growth corridor (*independent_provider_analysis.md*). One nuance from the 2026 regulatory shift actually *favors* RCH: **SB351 excludes hospitals from the PE/hedge-fund CPOM restrictions**, so RCH can build MSO/foundation structures that PE-backed entrants now find harder (*california_regulatory_requirements.md*).

### The two binding constraints — and the structural openings

**Most-constraining forces: Supplier power (physicians) and Rivalry.** Both trace to the same root — RCH is sub-scale and its physician supply is being absorbed by a payer-owned group it cannot legally out-employ. These two forces, working together, are what a Five-Forces analysis would call the determinants of this segment's low attractiveness for a standalone.

The openings are equally precise, and each maps to a weak or absent rival:
- **Aggregate the ~320 independent PCPs into an RCH-led CIN** (anchors CAMG and a now-independent RYMG; Arrowhead Orthopaedics for specialty depth; All United/MedEx/SoCalHealth IPAs for risk-bearing attribution). This directly attacks the #1 binding force — supplier power — by giving RCH an attributable, defensible physician base instead of one owned by Optum. A first-wave panel of ~80,000-150,000 lives is realistic against a ~700,000 ceiling (*independent_provider_analysis.md*).
- **The San Gorgonio Pass corridor** is under-bedded (one fragile 79-bed district hospital at 27.5% occupancy) — the clearest geographic lane before LLU/Kaiser entrench.
- **The convenient-access front door Optum abandoned in 2024** (urgent-care closures in Beaumont/Highland/Redlands) is an opening to own access in RCH's own city.
- **An ASC strategy** converts the substitution threat into captured outpatient margin.

In Ginter's adaptive-strategy terms (Ch. 8), these openings point not to a defensive *status-quo/enhancement* posture but to **vertical integration (backward, into primary care) and market development (the Pass)** — the structural response to a market where the two binding forces are physician supply and scale-based rivalry.

---

# 3. Market Demand, Leakage & Trend Analysis

## Market Demand, Leakage & Trend Analysis

### 1. The leakage picture: a strong ED door, a leaky inpatient floor

RCH's competitive position depends entirely on how the market is framed. In the **core draw area** — the six ZIPs where RCH is the home hospital (Redlands 92373/92374/92375, Yucaipa 92399, Mentone 92359, Calimesa 92320) — 15,513 inpatient discharges originated in CY2024 and RCH captured 5,712, a **36.8% inpatient market share / 63.2% leakage** (HCAI Patient Origin/Market Share, CY2024; `rch_market_share_leakage.csv`). Widen the lens to all 17 project ZIPs (which reach into the City of San Bernardino, anchored by St. Bernardine, Community Hospital of SB, and Arrowhead) and RCH's share collapses to **13.5%** — but that figure is diluted by ZIPs outside RCH's realistic catchment. The 36.8% core figure is the honest read.

Where the core leak goes is decisive for strategy because it splits into recapturable and structural buckets:

| Destination | Core discharges | % of core market | Nature of leakage |
|---|---|---|---|
| **Redlands Community (RCH)** | 5,712 | **36.8%** | (retained) |
| Loma Linda Univ Med Ctr | 2,970 | 19.1% | Tertiary / Level I trauma / academic |
| LLU Children's | 1,447 | 9.3% | Pediatric tertiary (RCH cannot serve) |
| Kaiser Fontana | 1,661 | 10.7% | Closed-network (Kaiser members) |
| Arrowhead Regional | 637 | 4.1% | Level I trauma / county safety-net |
| St. Bernardine | 530 | 3.4% | Community-acuity (recapturable) |
| All other CA hospitals | 2,556 | 16.5% | Mixed; largely recapturable |

*Source: `rch_market_leakage_analysis.md` core-area table; residual computed from totals.*

The **Loma Linda system together pulls ~28%** of RCH's home inpatient volume and **Kaiser Fontana ~11%** (HCAI CY2024). The single clearest structural driver visible in the data is acuity: LLUMC and Arrowhead are the region's only two Level I trauma/academic centers, and they are also the two running hottest on occupancy (LLUMC 109%, Arrowhead 86% vs RCH 56.6%) — the leak is partly RCH sending away cases it is not equipped to keep.

### 2. The ED–inpatient asymmetry: RCH already owns the patient

RCH is a far stronger **ED** magnet than inpatient magnet, and the gap is the strategic key. In its home ZIPs, ED share runs 53–59% while inpatient share runs 27–42% — a persistent 13-to-26-point gap:

| Home ZIP | IP share | ED share | ED-minus-IP gap |
|---|---|---|---|
| 92373 Redlands | 42.3% | 59.4% | +17.1 pts |
| 92374 Redlands | 31.7% | 57.9% | +26.2 pts |
| 92399 Yucaipa | 39.9% | 53.2% | +13.3 pts |
| 92359 Mentone | 33.9% | 58.9% | +25.0 pts |
| 92320 Calimesa | 26.5% | 33.0% | +6.5 pts |

*Source: `rch_market_share_leakage.csv` (Inpatient vs ED_Only rows).*

Yucaipa (92399) is RCH's **#1 inpatient feeder** (2,212 discharges, 19.8% of all RCH inpatients) and its #1 ED feeder (8,344 visits, 17.8%) — making the San Gorgonio Pass arc (Yucaipa → Calimesa → Beaumont/Banning) the natural expansion axis (`rch_patient_origin.csv`). RCH sees these residents in its ED at a ~55% rate but admits only ~37% of the area's inpatient cases. The strategic implication: RCH does not have an awareness or access problem — it has a **conversion/retention** problem. The patients already walk through its doors; they leave for the admission. Closing even half of this ~18-point conversion gap is the lowest-cost recapture lever available, requiring care-coordination, transfer-prevention, and service-line build-out rather than new market access.

### 3. Trending the trajectory: demand is leaving the inpatient floor

The six-year HCAI utilization series shows RCH living through the industry-wide inpatient-to-ambulatory shift in an acute form:

| Metric | 2018 | 2022 | 2024 | 6-yr change | CAGR |
|---|---|---|---|---|---|
| Total discharges | 13,946 | 10,180 | 9,604 | **−31.1%** | −6.0%/yr |
| Newborns/births | 2,161 | 1,689 | 1,336 | **−38.2%** | −7.7%/yr |
| ED visits | 38,904 | 52,739 | 55,847 | **+43.6%** | +6.2%/yr |
| Outpatient surgeries | — | 3,299 | 3,871 | +17.3% (2yr) | — |
| Inpatient surgeries | — | 3,066 | 2,854 | −6.9% (2yr) | — |
| ALOS (days) | 3.5 | 4.4 | 4.5 | +28.6% | +4.3%/yr |

*Source: `rch_hospital_data.md` §4 (HCAI Annual Utilization, CY2018/2022/2024).*

Three signals stand out. First, **volume is migrating from beds to the ED and the ambulatory suite**: indexed to 2018, ED visits are at 144 while discharges are at 69 — they have moved in opposite directions, and outpatient surgery now outnumbers inpatient surgery 57.6% to 42.4% of the surgical mix. Second, **rising ALOS (3.5→4.5 days) alongside falling discharges** signals an acuity/case-mix shift — the easy, short-stay cases are increasingly done outpatient or lost to competitors, leaving a sicker, longer-staying residual inpatient population. Third, the **ED admit-conversion rate collapsed from 21.4% (2018) to 10.1% (2024)** — RCH's ED is growing as a treat-and-release engine but feeding proportionally fewer admissions, reinforcing the conversion-gap thesis. If the −6.0%/yr discharge trend continues unchecked, RCH projects to ~7,970 discharges by 2027 — making recapture not optional growth but a defense against erosion. The collapsing birth volume (−38%) is its own strategic flag: the OB service line is shrinking toward a sub-scale, fixed-cost-heavy footprint that will force a keep/contract decision.

### 4. Sizing the recapture prize

Using HCAI's CY2024 net inpatient revenue of $167,573,733 divided by 9,604 reported discharges yields **~$17,448 net IP revenue per discharge** (a conservative basis; an origin-volume denominator of 11,162 gives a lower $15,013 — both shown). Lifting core inpatient share from today's 36.8%:

| Target core IP share | Core discharges | Incremental vs 5,712 | Incr. net IP rev @ $17,448 | (sensitivity @ $15,013) |
|---|---|---|---|---|
| 36.8% (today) | 5,712 | — | — | — |
| **42%** | 6,515 | **+803** | **+$14.0M** | +$12.1M |
| **46%** | 7,136 | **+1,424** | **+$24.8M** | +$21.4M |
| **50%** | 7,756 | **+2,044** | **+$35.7M** | +$30.7M |

*Estimates. Source: core total 15,513 (`rch_market_leakage_analysis.md`); rev/discharge from HCAI net IP rev (`rch_hospital_data.md` §3.2).*

Against RCH's FY2024 ~$8.6M operating loss, even the 42% scenario (+$14.0M) flips the operating line; the capacity exists (56.6% GAC occupancy, ~195 GAC beds).

**Critically, not all 63.2% leakage is winnable.** Decomposing the 9,801 leaked core discharges:

| Bucket | Est. discharges | % of leak | Recapturable? |
|---|---|---|---|
| Kaiser closed-network (Fontana et al.) | ~1,661 | ~17% | No — Kaiser members |
| True tertiary/peds/trauma (≈60% of LLU+Arrowhead pool) | ~3,032 | ~31% | No — RCH has no trauma/quaternary/peds-tertiary capability |
| **Community-acuity leak (residual)** | **~5,108** | **~52%** | **Yes — within RCH's scope** |

*Labeled estimate; tertiary split is an analyst assumption (~60% of LLU-system + Arrowhead volume genuinely tertiary). Source basis: core competitor volumes, `rch_market_share_leakage.csv`.*

The structurally recapturable pool (~5,108 discharges) implies a **realistic share ceiling near 70%**, not 100% — but is worth ~**$89M** in net IP revenue at full capture. No standalone community hospital recaptures all of it; the credible near-term target is the 42–46% band (+$14–25M), achieved by converting the ED franchise, building ortho/spine and cardiac depth where RCH is already US-News "High Performing," and aligning the Yucaipa/Pass corridor through a clinically integrated network so referrals default to RCH rather than the Loma Linda magnet.

---

# 4. Internal Capability, Value Chain & Financial Diagnostic

## Internal Capability, Value Chain & Financial Diagnostic

### 1. Resource & Capability Inventory — VRIO Screen

Applying the Ginter (Ch. 8) strategic-resources lens and a VRIO test (Valuable, Rare, costly-to-Imitate, Organized-to-exploit), RCH's asset base splits cleanly into two genuinely defensible competencies, a cluster at competitive parity, and several liabilities masquerading as strengths.

| Resource / capability | Valuable | Rare | Costly to imitate | Organized | Verdict | Evidence |
|---|---|---|---|---|---|---|
| **Dominant local ED front door** | Yes | Yes (no walk-in substitute in core ZIPs) | Yes (24/7 fixed cost + EMS routing + Title 22 licensure) | Partial | **Sustained advantage** | 61,472 ED visits 2024; ~57-59% home-ZIP ED share; +44% visits since 2018 (38,904→55,847) — *hcai_utilization_comparison.csv; rch_hospital_data.md §4* |
| **Ortho/spine surgical excellence** | Yes | Yes | Yes (surgeon talent + reputation) | Yes | **Sustained advantage** | US News High Performing: spinal fusion, hip, knee, pacemaker; Healthgrades America's 100 Best Ortho 2025; hip/knee readmit 0.962 (better than expected) — *rch_quality_scores.csv* |
| 120-yr independent local brand / "keep care local" | Yes | Yes | Yes (time) | Weak | **Latent advantage (under-organized)** | Founded 1904; only independent NFP acute hospital in core draw area — *rch_hospital_data.md §1* |
| #3 employer / community anchor / $58.1M community benefit | Yes | Moderate | Moderate | Partial | **Temporary advantage** | 1,847 employees (4.99% of city jobs); FY2023 community benefit $58.1M — *rch_hospital_data.md §1, §3.3* |
| Maternity & cancer (CoC) programs | Yes | No | No | Yes | **Parity (eroding)** | Maternity Honor Roll 2025; CoC accredited 2025-27; but births -38% (2,161→1,336) — *rch_hospital_data.md §2.9, §4* |
| Capacity headroom (56.6% GAC occupancy) | Yes | No | No | No | **Parity / underused asset** | 9,320 GAC discharges on 195 GAC beds vs. LLUMC 109%, Arrowhead 86% — *hcai_utilization_comparison.csv* |
| Quality reputation / star rating | — | — | — | — | **Liability** | CMS 2/5 live; markets 4/5; stroke mortality 18.5 "Worse than national" — *rch_quality_scores.csv* |
| Employed physician base | — | — | — | — | **Absent (CPOM-constrained)** | No 1206(l) foundation today; Optum/Beaver owns the multispecialty base — *engagement brief* |

The strategic read: RCH's two real moats (ED gravity, ortho) are both **point-of-service** capabilities. It has almost nothing defensible in the **pre-service** (access, primary care, prevention) or **after-service** (care coordination, population management) layers — precisely the layers the Redlands Health vision must build. That is the internal gap the strategy exists to close.

### 2. Weaknesses & Vulnerabilities — Quantified

| Vulnerability | Magnitude | Strategic consequence |
|---|---|---|
| Inpatient volume collapse | Discharges -31.1% (13,946→9,604, 2018-24) | Fixed-cost deleveraging; the acute core is shrinking faster than reimbursement can offset |
| Birth-volume erosion | Newborns -38.2% (2,161→1,336) | Threatens OB service-line viability; commercial-payer-rich line |
| Rising ALOS | 3.5 → 4.5 days (HCAI) | Throughput inefficiency; ~1 extra day on declining volume signals case-mix/discharge-planning weakness |
| Quality credibility gap | CMS 2/5 live vs. 4/5 marketed | Reputational/legal exposure; undermines payer and CIN-recruitment leverage |
| Stroke mortality | 18.5%, "Worse than national" | Specific clinical liability; reinforces leakage to Loma Linda (Level I / academic) |
| Leapfrog non-participation | Graded C, then "Not Assigned" since Fall 2024 | Signals defensiveness; sophisticated self-funded employers read non-participation as a red flag |
| No employed MDs (CPOM) | 0 vs. Optum/Beaver ~1,000 | Gating constraint on at-risk contracting and leakage capture |
| Thin/negative margins | Operating loss 6 of 14 yrs; FY2024 -$8.6M | No internal cash engine to fund transformation |

### 3. Value Chain (Ginter Ch. 8) — Where Value Leaks vs. Adds

| Stage | Current state (sourced) | Value leak / add |
|---|---|---|
| **Pre-service** (access, scheduling, primary care, prevention) | Two safety-net clinics only; no owned PCP base; Optum/Beaver controls referral funnel | **Biggest leak.** RCH does not control the front of the funnel, so demand is captured by payer-owned primary care upstream |
| **Point-of-service** (acute, surgery, ED, OB) | ED 61,472 visits/yr (strength); ortho/spine excellence; OB & cancer accredited but declining; stroke mortality weak | **Strongest link, but narrowing.** Ortho + ED are the value-creating core; OB/med-surg are leaking volume |
| **After-service** (discharge, follow-up, care coordination, population health) | Readmissions at/below expected (HF 0.948, hip/knee 0.962) — operationally adequate; but no CIN, no longitudinal management | **Leak + opportunity.** Adequate readmissions but zero population-health infrastructure; this is where value-based revenue would be captured |
| **Support — culture** | 120-yr "keep care local" identity; community anchor | Asset; underleveraged in marketing/recruitment of independent MDs |
| **Support — structure** | Independent standalone NFP; no foundation/MSO/CIN | Liability for at-risk strategy; CPOM forces a structural build before scale |
| **Support — strategic resources** | 56.6% occupancy headroom; $57.5M net assets; brand | Headroom is a real add (room to in-source leaked volume) but capital is thin |

**Net:** RCH creates value almost entirely at the point of service and leaks it at both ends of the chain. The vertical-integration thesis is, in value-chain terms, a deliberate **forward integration into pre-service (primary care/access) and after-service (population health)** to stop the leakage and convert ED gravity into longitudinal, at-risk relationships.

### 4. Financial Diagnostic — 14-Year Trajectory (IRS Form 990, EIN 95-1643347)

| Metric | FY2011 | FY2017 (peak NA) | FY2023 | FY2024 | Source |
|---|---|---|---|---|---|
| Total revenue | $261.0M | $319.5M | $418.3M | $407.1M | *rch_financials_utilization.csv* |
| Total expenses | $259.5M | $311.1M | $402.1M | $415.7M | same |
| Operating margin | +0.6% | +2.6% | +3.9% | **-2.1%** | same |
| Net assets | $49.6M | **$79.8M** | $64.8M | $57.5M | same |
| CEO comp | n/i | $0.87M | $0.82M | $1.17M | same |

Key findings from the series:
- **Revenue grew ~3.5% CAGR (2011-2024) — but this masks a volume collapse.** Top-line growth is almost entirely rate/case-mix and outpatient shift, not demand. Net outpatient revenue ($232.5M) now exceeds net inpatient ($167.6M); **outpatient = 58% of net patient revenue** (HCAI FY2024), tracking the surgery mix (outpatient surgeries +17%, inpatient -7%).
- **Operating losses in 6 of 14 years** (2014, 2018, 2019, 2021, 2022, 2024). The hospital has repeatedly relied on non-operating gains (investment returns) to reach positive bottom lines — a fragile model in a volatile-rate environment.
- **Net assets fell 28% from the 2017 peak** ($79.8M → $57.5M, -$22.3M), even as revenue rose — the balance sheet is being slowly consumed.
- **FY2024 CEO compensation ($1.17M) equals ~14% of the year's $8.6M operating loss** — an optics and governance flag for a board contemplating a capital raise.

**Balance-sheet capacity to fund transformation:** At $415.7M FY2024 expenses, daily operating cost is ~$1.14M. Net assets of $57.5M represent roughly **51 days of total operating cost** — and most of that is illiquid (PP&E, restricted funds), so true unrestricted liquidity is materially lower. **RCH cannot self-fund a multi-year, multi-entity vertical-integration build from the balance sheet.** A CIN/foundation/MSO build, ambulatory expansion, and any Knox-Keene reserve requirement would each draw capital RCH does not have in reserve.

### 5. What Must Be True Financially to Invest

1. **Stop the operating bleed first.** Return to a sustained ≥3% operating margin (achieved only in 2012, 2013, 2015-17, 2020, 2023) before committing growth capital — fund the pivot from operations, not the corpus.
2. **Monetize the underused asset.** 56.6% occupancy and outpatient-surgery growth argue for harvesting ambulatory/ortho cash flow (the VRIO-positive lines) to seed the prevention build — a classic Ginter **harvesting-to-fund-expansion** sequencing.
3. **Stage the entity build to defer capital.** Start CIN/shared-savings (no Knox-Keene license, low capital) before global risk or own-the-plan (reserves). Phase capital to volume capture.
4. **Use external/partnership capital.** With ~51 days of cushion, a JV, philanthropic capital campaign (leveraging the 120-yr brand and $58M community-benefit narrative), or a managed-services partner is likely required — not a balance-sheet-funded go-it-alone.
5. **Close the quality-credibility gap immediately** — restore Leapfrog participation, remediate stroke mortality, reconcile the 2-star/4-star marketing — because every payer, employer, and physician-recruitment conversation prices RCH's credibility, and that is currently a self-inflicted discount.

---

# 5. Payer, Employer, Covered-Lives & Physician-Supply

## Payer, Employer, Covered-Lives & Physician-Supply

### The strategic frame (Ginter)

This workstream is the demand-and-supply core of RCH's vertical-integration thesis. In Ginter's adaptive-strategy taxonomy, owning/aligning primary care and monetizing covered lives is **forward vertical integration** (toward the patient/payer) plus **related diversification** into insurance functions. The market-entry mechanism is deliberately **cooperation (alliance/CIN), not purchase** — California's Corporate Practice of Medicine bar makes employment impossible, so RCH builds through contracting first. The competitive posture is **focused differentiation** (Porter): a locally-owned, prevention-first network defending its home draw against three larger but structurally constrained rivals.

### 1. Covered-lives sizing — a 22,000-life prize against a 1,405-life baseline

The lives model is a transparent top-down funnel anchored on EDD city employment, with every assumption exposed (source: `market-analysis.html`, methodology section):

| Funnel stage | Lives | Assumption |
|---|---:|---|
| Jobs in city of Redlands | 37,000 | EDD via City ACFR FY2025 |
| Commercial covered lives via employers | ~36,000 | ~55% take-up x ~1.8 lives/enrollee |
| **Capturable (non-Kaiser)** | **~22,000** | excludes ~40% Kaiser-locked |
| Near-term direct-contract wedge | ~3,000-5,000 | self-funded + anchor employers |
| **RCH's own plan today (baseline)** | **1,405** | DOL Form 5500, FY2024 |

The capturable pool is **15-20x** the 1,405 lives RCH covers today. Sensitivity to the two swing variables (take-up, Kaiser share) keeps the prize material across the grid:

| Kaiser share / take-up | 45% | 55% | 65% |
|---|---:|---:|---:|
| Kaiser 35% | ~19,500 | ~23,800 | ~28,100 |
| **Kaiser 40% (base)** | ~18,000 | **~22,000** | ~26,000 |
| Kaiser 45% | ~16,500 | ~20,100 | ~23,800 |

Even the pessimistic corner (45% Kaiser, 45% take-up) yields ~16,500 capturable lives. **The constraint is execution, not market size** (`market-analysis.html`).

### 2. Who insures Redlands — the carrier map and the self-funded wedge

Among the 82 insured employers physically in Redlands on public record, carrier *presence* (employers can carry more than one) breaks down as below. The strategically decisive row is **self-funded**: these employers bear their own claims risk and can direct-contract with RCH today with **no health-plan license required** (source: `market-analysis.html` §3; `health_plan_carriers_by_employer.csv`).

| Carrier | In-city employers | Capturability |
|---|---:|---|
| Kaiser (closed) | 33 | Uncapturable — the wall |
| Anthem Blue Cross | 12 | Open PPO/HMO — capturable |
| UnitedHealthcare | 11 | Open — but Optum-affiliated payer |
| Blue Shield of CA | 6 | Open — capturable |
| Aetna | 5 | Open — capturable |
| Cigna | 4 | Open — capturable |
| Health Net | 2 | Open — capturable |
| **Self-funded** | **12 in-city / 64 wider** | **Direct-contract wedge, no license** |

Roughly **40 open-network employer relationships** plus **12 self-funded plans** are reachable. The ~40% Kaiser presence is out of scope, not a conversion target. Across the wider national-filer roster (`health_plan_carriers_by_employer.csv`, 285 employers), 64 carry no insured medical line — the self-funded population that an RCH center-of-excellence / bundled-rate offer can target directly.

### 3. The employer base — anchor and on-site-clinic targets

The top employers concentrate lives and are the natural first calls for direct-to-employer contracting and on-site/near-site clinics (source: `redlands_top_employers.md`, City ACFR FY2025; `redlands_5500_health_plans.csv`):

| Employer | Employees | Plan participants (5500) | Carrier posture | Play |
|---|---:|---:|---|---|
| Redlands Unified SD | 2,433 | (govt, no license) | — | On-site clinic / direct contract |
| ESRI | 2,416 | 4,890 | **Cigna ASO (self-funded)** | Prime direct-contract / wellness anchor |
| **Redlands Community Hospital** | 1,847 | 1,405 | Self-insured | Convert own employees to network first |
| Optum/Beaver | 1,000 | — | UnitedHealth-owned | Competitor — not a target |
| City of Redlands | 539 | — | — | Direct contract |
| Amazon (city FC) | 526 | company-wide | Kaiser HMO + Cigna | Logistics on-site clinic |
| University of Redlands | 471 | 591 | UHC/self | Direct contract |

ESRI is the standout: a self-funded technology employer (Cigna administering health, dental, vision) with 4,890 plan participants — the single largest local self-funded relationship and the highest-value direct-contract target (`redlands_5500_health_plans.csv`). RCH should also **convert its own 1,405-life plan** into the network's proof-of-concept and the seed for a provider-sponsored plan.

### 4. The physician-supply gate — Optum-owned dominance vs. an independent CIN

This is the binding constraint. Optum/Beaver (UnitedHealth-owned, the #4 employer, ~11 offices plus Optum Care Network-San Bernardino and the Optum/NAMM-owned Inland Faculty Medical Group at 900+ providers/230K+ lives) is simultaneously the dominant group **and** owned by a competitor payer (`independent_provider_analysis.md` §2). RCH cannot out-scale it; it must aggregate what remains independent.

The defensible counter is a **CIN built on ~320 independent corridor physicians** (NPPES census), translating to **~270-490 panel-carrying PCP-FTE** after haircuts, touching a theoretical **~0.5M-0.9M lives** (centered ~700k at 400 PCP-FTE x 1,800 lives). The **realistic first-wave landing zone is ~80,000-150,000 manageable lives** (`independent_provider_analysis.md` §4):

| Aggregation target | PCPs | Rough lives | Strategic note |
|---|---:|---|---|
| **CAMG** (Redlands) | 13 | 18k-26k | Founded 2024 to keep care local — the natural CIN nucleus |
| **RYMG** (Yucaipa) | 30-45 | 55k-80k | Just left Optum; landing it ~doubles the PCP base |
| **Arrowhead Orthopaedics** | 27+ surgeons | — | Largest independent IE ortho; feeds RCH Spine & Joint |
| IPAs: All United / MedEx / SoCalHealth | 40-95 | 47k-110k | Risk-bearing IEHP attribution + infrastructure |
| LaSalle (in-corridor slice) / Maren | — | partial of 300k+ | Medi-Cal IPA depth; Dr. Arteaga relationship |

The risk pyramid, adjusted up for Inland Empire chronic-disease load (SB County diabetes 17.0%, HTN 30.2%, obesity 36.5% — each above CA average), runs **~77.5% healthy / ~15-17% rising-risk / ~5-6% high-risk complex**. On a ~120k first-wave panel that is **~6,000-7,200 high-utilizers** — the ~5% who drive ~50% of cost and the financial engine of any value-based contract.

### 5. The risk ladder — quantifying lives and value at each rung

RCH should climb deliberately, banking lives and physician alignment before bearing insurance risk. The Knox-Keene ladder maps to the California regulatory reality: shared-savings needs no license; global risk needs a Restricted Knox-Keene; owning the plan needs full Knox-Keene plus reserves (`market-analysis.html` §4; `california_regulatory_requirements.md`).

| Rung | Mechanism | Best target | Near-term lives | License | Value logic |
|---|---|---|---:|---|---|
| 1. Direct-to-employer | Bundled/case rates, COEs, on-site clinic | 12 self-funded local / 64 wider; ESRI, RUSD | ~3k-5k | None | Capture leaked elective volume; ortho/spine COE |
| 2. Narrow/tiered network | RCH-centered network rented to carrier/TPA | ~40 open-PPO employers | ~8k-12k | None | Steerage + better unit economics |
| 3. CIN / ACO | Independent MDs + RCH, value-based | Independents; Medicare; payers | ~80k-150k | ACO rules / shared-savings | Shared savings on ~5% high-cost tier |
| 4. Provider-sponsored plan | RCH bears insurance risk, sells coverage | Whole market | toward ~22k commercial + MA | **Restricted -> full Knox-Keene + reserves** | Full premium capture + medical-loss control |

Each rung is a strategic-control checkpoint: RCH only advances when attributed lives and care-management infrastructure justify the next regulatory burden. Rungs 1-3 require **zero or light** licensure and can begin immediately; Rung 4 is the multi-year endgame.

### Bottom line for this workstream

The market is large (~22k capturable lives, ~15-20x today's 1,405), the carrier map is legible (40% Kaiser-locked, ~60% reachable), and the wedge is sharp (12 self-funded in-city employers, ESRI foremost). The gate is physician supply, and the answer is a CIN aggregating ~320 independents — CAMG and a now-independent RYMG as anchors, Arrowhead for specialty depth, the IPAs for risk-bearing attribution — landing ~80k-150k first-wave lives. RCH should climb the risk ladder rung by rung, converting its own 1,405-life plan into the seed and Knox-Keene-licensing only after the CIN proves it can manage the IE's heavy high-cost tier.

---

# 5A. Resident vs. Commuter Market Read — Network Efficiency by Residence

*Added after the core engagement, in response to a market-entry question: are Redlands and its neighbors local/self-contained or commuter communities, and how should that reshape the covered-lives model? Sources: U.S. Census LEHD LODES8 (data year 2022, JT01/S000) and ACS 2024 5-year; full detail in `commuter_resident_analysis.md` and `commute_flows_by_city.csv`. All figures are estimates (LODES is noise-infused/UI-covered-employment; ACS carries sampling error).*

**The principle.** A covered-lives count anchored on *employer location* (people who work at a Redlands employer, via Form 5500) is not the same market as *residence* (people who live in the service area). A provider network's value to a member is governed by where that member **lives** — time/distance, network adequacy, where they actually seek longitudinal care — not where they work. The Census commuting data shows the two populations are largely **different people in different places**.

**Redlands is a net in-commute employment center inside a ring of bedroom communities.**

| Metric (Redlands) | Value | Read |
|---|---|---|
| Primary jobs in city | 39,161 | Daytime job magnet (ESRI, RUSD, RCH, Optum, U. of Redlands, Amazon) |
| Held by residents (live+work) | 5,836 = **14.9%** | Only ~1 in 7 local jobs is filled by a resident |
| Filled by in-commuters | 33,325 = **85.1%** | ~two-thirds live *outside* the efficient (~15-min) service area |
| Jobs-housing ratio | **1.26** | Net employment importer — pulls workers in |
| Employed residents | 30,755 | … of whom only 19.0% work in Redlands |
| Out-commuters | 24,919 = **81.0%** | But mostly stay close (San Bernardino 17%, Loma Linda 9.5%) — still efficient resident lives |
| Mean commute | ~24.9 min | Shortest of the bedroom communities; 13.8% WFH (highest in set) |

**Regional pattern.** No city in the study area is self-contained. **Loma Linda (jobs-housing 2.15)** and **San Bernardino (1.45)** are in-commute employment centers; **Yucaipa, Highland (0.26), Mentone, Grand Terrace, Calimesa, Beaumont, Banning** are out-commute bedroom communities (0.26–0.50) that export 89–98% of their employed residents — dense reservoirs of *resident* lives whose care defaults home.

**Three populations, two lines of business.**
- **Resident lives — "own the relationship."** Everyone who *lives* in the efficient service area (Redlands + the bedroom-community ring + resident out-commuters). Strategy: longitudinal and total-cost-of-care — CIN, primary care, value-based/ACO, a provider-sponsored/co-branded plan. Sticky, because home doesn't move with a job change. The jobs-housing<1 dormitories are an **asset**, not a liability.
- **Daytime-worker lives — "serve episodically, payer-agnostic."** The ~33,000 who *work* in Redlands but live elsewhere (and the analogous daytime populations in Loma Linda and San Bernardino). Strategy: point-of-care and convenience — occupational health, near-site/on-site employer clinics (ESRI, Amazon, the District, RCH itself, the donut-hole DCs), urgent care and imaging near the employment corridors, ED/ASC capacity, and **Centers of Excellence** (ortho/spine, cardiac, oncology) + **direct-to-employer bundles** that *any* payer routes to on price/quality regardless of where the patient lives. Do **not** try to make these workers' families members of an RCH narrow network — capture the **episodes** that occur during the workday and the high-acuity referrals that travel for reputation.

**How to account for it in the covered-lives model.**
1. **Apply a residence haircut.** Size the narrow-network / provider-sponsored-plan TAM on roughly **0.40–0.45 × employer-based lives**, not 1.0× — only the ~14.9% who live+work plus the ~32% near-resident slice of in-commuters originate inside the efficient service area. Treat the remaining ~55–60% as out-of-area worker lives that won't anchor longitudinally.
2. **Add resident out-commuters back in.** The ~24,900 Redlands residents (plus tens of thousands more across the bedroom-community ring) insured by out-of-area employers are invisible to an employer count but fully addressable on a residence basis. Build the resident-lives TAM from Census household population, not the local employer roster.
3. **Build a separate daytime/worksite services line** sized on the **full ~39,000-job daytime base** (plus ~22,000 Loma Linda, ~119,000 San Bernardino), modeled as episodic/B2B (occ-health PMPM/PEPM, near-site clinics, urgent-care/imaging volume, ED/ASC throughput, bundled COE referrals) — economics that don't depend on owning the member's insurance.
4. **Use residence as the unit of geography for anything longitudinal; use workplace geography only for the worksite/COE line.** The single most important modeling error to avoid is letting the impressive 39,000-job workplace number set the size of a *plan* whose members must, by the data, mostly live somewhere else.

*Note on the "donut hole": Redlands is encircled by an unincorporated county island (Citrus Plaza / Mountain Grove with the Burlington & Amazon DCs) whose jobs sit outside the city line, so 39,161 understates true Redlands-area daytime employment — drawing the service area around the hospital rather than the city boundary only strengthens the in-commute-employment-center conclusion.*

---

# 6. Regulatory & Deal-Structure Navigation: The Compliant Path Through California's Waters

## Workstream 6 — Regulatory & Deal-Structure Navigation: The Compliant Path Through California's Waters

California regulation is not a wall around the "Redlands Health" vision — it is a channel. Every constraint has a legally-recognized navigation path; the strategic art is **sequencing** the moves so RCH never triggers a more burdensome regime than the current step requires, and so the two 2026 statutes (SB 351, AB 1415) are used as tailwinds rather than headwinds. This chapter translates each California constraint into a `constraint → compliant path → when` instruction, then ties the sequence together into a single regulatory roadmap. *(Source for all statutory citations: `california_regulatory_requirements.md`.)* Framework note: this is the **Implementation + Strategic Control** stage of the Ginter strategic-management process — the structural plumbing beneath the adaptive strategy (vertical integration / market development) and the market-entry strategy (cooperation/alliance before purchase/acquisition).

### 6.1 CPOM — "RCH can't employ physicians." The three-structure ladder.

Business & Professions Code §2400 bars a lay corporation — which a private NFP community hospital is — from employing physicians or controlling clinical judgment. RCH does **not** qualify for the district/county/UC exceptions. So the primary-care base must be built through one of three structures, which differ sharply in capital, control, and regulatory bar:

| Structure | Capital / build | Clinical control to RCH | Statutory bar | Sequence role |
|---|---|---|---|---|
| **IPA / CIN (contract only)** | Lowest; contracts, not equity | Lowest (alignment, not control) | None (antitrust integration test only) | **Start here (Year 0–1)** |
| **Friendly-PC + MSO** | Moderate; MSA + IT/RCM build | Moderate (admin control via MSA; clinical stays in PC) | SB 351 clinical-control limits | **Layer next (Year 1–3)** |
| **§1206(l) Medical Foundation** | Highest; real institutional build | Highest ("employed-equivalent") | **40+ MDs, ≥10 specialties, ≥⅔ full-time, + research & health-education mission** | **Convert into (Year 3–6)** |

**Recommended sequence — do NOT jump to the foundation first.** The §1206(l) bar (40+ physicians, 10+ board-certified specialties, two-thirds full-time, *plus* a genuine research-and-education mission) is a multi-year institutional build that RCH cannot clear on day one. The aggregable independent base — **Community Alliance Medical Group (CAMG, ~13 PCPs), a now-independent Redlands-Yucaipa Medical Group (RYMG, ~30–45 providers), Arrowhead Orthopaedics (27+ surgeons), and the independent IPAs (All United, MedEx, SoCalHealth, LaSalle slice)** — is a contracting opportunity *today*, not an employment opportunity. The path:

1. **Year 0–1: stand up an RCH-sponsored CIN and an MSO.** The CIN aggregates the ~320 independent corridor PCPs (`independent_provider_analysis.md`) for joint contracting; the MSO sells back-office, IT, RCM, and care-management to those same groups — capturing economics and alignment without touching clinical control or CPOM.
2. **Year 1–3: add a friendly-PC + MSO for owned-equivalent capacity** where RCH needs a controllable PCP supply (e.g., the Beaumont/Banning Pass whitespace). The physician-owned PC employs the doctors; the MSO (RCH-affiliated) runs admin under a management services agreement.
3. **Year 3–6: convert the aggregated group into a §1206(l) foundation** once the network clears 40+ physicians / 10+ specialties. The corridor's independent census easily supports this — the constraint is *organizing* it, not *finding* it. RCH's existing CoC cancer program, ortho/spine institute, and academic affiliations seed the required research/education mission.

### 6.2 SB 351 (eff. 1/1/2026) — codified CPOM that *excludes hospitals*: reframe as RCH's structural advantage.

SB 351 codifies CPOM and bars **private-equity groups and hedge funds** from controlling clinical decisions or imposing noncompete/non-disparagement terms — but **hospitals, hospital systems, and public agencies were explicitly excluded** from the "PE group / hedge fund" definitions. This is a genuine competitive asymmetry RCH should exploit in physician recruiting:

| Acquirer of a physician group | Can use MSO control levers? | Can impose noncompetes? | SB 351 exposure |
|---|---|---|---|
| **PE-backed platform / aggregator** | Restricted | **No** | High — AG enforcement target |
| **Optum/Beaver (payer-owned)** | Restricted as PE-adjacent; payer-conflict optics | Constrained | Elevated; UnitedHealth ownership is a recruiting liability |
| **RCH (NFP hospital, SB 351-excluded)** | **Permitted within CPOM limits** | Within physician-PC limits | **Lowest** |

**The pitch to CAMG, RYMG, and the independents:** "Align with a community nonprofit hospital that the legislature exempted from the PE clamp-down — not a private-equity roll-up the AG is now policing, and not the payer (UnitedHealth/Optum) that owns your gatekeeper." This is an **ST (defensive) TOWS move**: use RCH's NFP-hospital strength against the threat of PE/payer consolidation. **When:** weave into every CIN/MSO term sheet from 1/1/2026 forward.

### 6.3 The Knox-Keene risk ladder — license to the rung you're on, never above it.

Bearing insurance risk triggers the Knox-Keene Act (H&S §1340 et seq., DMHC). The three rungs map directly onto RCH's value-based progression and onto the covered-lives model (~22,000 capturable commercial lives; only 1,405 on RCH's own plan today, per `health_plans_form5500.md`):

| Rung | Risk borne | License required | Reserve / infrastructure | When |
|---|---|---|---|---|
| **1. Shared savings / upside-only** | None (FFS + bonus) | **None** | Care-management only | **Now → Year 2** (MSSP-style ACO, commercial shared-savings with Anthem/UHC/Blue Shield) |
| **2. Global / downstream risk** | Professional + institutional capitation | **Restricted Knox-Keene (RKKL)** + RBO solvency (Title 28 §1300.75.4) | DMHC financial-solvency standards, claims-payment | **Year 2–4** (capitated IEHP/Medi-Cal and MA lives via the IPAs) |
| **3. Own the plan** | Full insurance risk; sell to employers | **Full Knox-Keene** | **Tangible net equity reserves**, TPA, network-adequacy filings | **Year 5+** (provider-sponsored plan for the ~22k commercial lives, self-funded employer direct contracts) |

**Sequencing instruction:** ride rung 1 to build attribution and care-management muscle at zero license cost; the IPAs RCH aggregates (All United, MedEx, SoCalHealth) already hold capitated IEHP lives, so RCH inherits rung-2 RBO infrastructure rather than building it. Pursue full Knox-Keene only after the CIN has demonstrated rung-2 solvency and the commercial covered-lives base (the 12 in-city / 64 wider self-funded employers — the direct-contract wedge) is contractually committed. **Do not file for a license the current contract structure doesn't require** — each rung up adds reserves and reporting.

### 6.4 OHCA / AB 1415 (eff. 1/1/2026) — the 90-day notice that governs deal *order*.

AB 1415 requires the Office of Health Care Affordability to receive **90-day advance notice** of "material change transactions" (acquisitions, affiliations, MSO deals) for deals closing on/after **April 2, 2026**, and OHCA may run a **Cost & Market Impact Review (CMIR)** that delays closing further. This is the binding constraint on *deal velocity*. Sequencing rules:

- **Front-load the sub-threshold moves.** A clinically-integrated *contracting* network and an MSO services agreement are lower-profile than an asset acquisition. Lead with these.
- **Stage acquisitions to stay individually below CMIR triggers** rather than bundling CAMG + RYMG + Arrowhead into one mega-transaction that invites a full market-impact review.
- **Start the 90-day clock the day a deal is board-credible**, in parallel with diligence, so the notice period runs concurrently rather than after.
- **Pre-wire OHCA and the AG** with the community-benefit narrative (below) so a CMIR, if triggered, resolves favorably.

### 6.5 The remaining waters — each constraint, its path, its timing.

| Constraint (source-of-truth) | Compliant navigation path | When |
|---|---|---|
| **AG review of NFP asset transfers** (Corp. Code §5914–5925) | Required AG notice + public meeting on any sale/control change of NFP health facility. Use **affiliation/MSO/CIN structures that are *not* asset transfers** for early moves; reserve AG-review transactions for later, high-conviction acquisitions. | Year 3+ (acquisitions only) |
| **Antitrust — CIN must be genuinely integrated to jointly contract** (FTC/DOJ; B&P §650/§650.01) | Independent physicians may jointly negotiate **only** if clinically *and* financially integrated. Build real shared EHR/care pathways, quality metrics, and shared financial risk before any joint payer contracting — otherwise it is per-se price-fixing. | Build integration in Year 0–1, *before* first joint contract |
| **Network adequacy** (H&S §1367.03; Title 28 §1300.67.2.2) | **1 PCP : 2,000 enrollees**; PCP within 15 mi/30 min; non-urgent primary-care appointment ≤10 business days; annual DMHC report by May 1. The 1:2,000 ratio means ~22k capturable lives need ~11–15 PCP-FTE teams — the same math that makes the 320 independent PCPs the gating asset. | Binds at rung-2/rung-3 licensure; design CIN panel coverage from Year 1 |
| **Seismic (Alquist Act, HCAI/OSHPD)** | SPC-2 compliance by **2030**; major construction needs HCAI plan review. Convert the looming capital requirement into the **ambulatory/ASC expansion** thesis — build new compliant outpatient capacity rather than only retrofitting the 211-bed tower. | Capital plan now; compliance by 2030 |
| **Community-benefit obligation** (H&S §127340 et seq.; charity care H&S §127400) | **Reframe as a strategic asset, not a cost.** RCH already files a community-benefits plan with HCAI (FY2023 community benefit ~$58.1M). Map the prevention-first, "healthiest-city," CIN, and Pass-corridor access agenda onto the *already-required* community-benefit and CHNA filings — this both satisfies the obligation and pre-builds the favorable narrative for AG and OHCA review. | Continuous; align with every transaction filing |

### 6.6 The integrated regulatory roadmap (the synthesis)

The throughline: **always operate at the lowest-burden compliant rung that the current strategic step requires, and use the 2026 laws as a wedge.** Year 0–1, RCH builds a CIN + MSO (no CPOM problem, no Knox-Keene license, no AG asset transfer, OHCA-light) and pitches SB 351's hospital exclusion to land CAMG and RYMG. Years 2–4, it moves to shared-savings then global risk (RKKL), inheriting IPA solvency infrastructure, while staging acquisitions one at a time under AB 1415's 90-day notice. Years 3–6, it converts the aggregated group into a §1206(l) foundation and, only when the commercial covered-lives base is committed, files for full Knox-Keene to own the plan. Every step is pre-wired with the community-benefit narrative that turns AG/OHCA review from a gate into a rubber stamp. The regulation is the channel; this is the chart for sailing it.

---

# 7. SWOT → TOWS: "Redlands Health" Vertical-Integration Strategy

## SWOT → TOWS: "Redlands Health" Vertical-Integration Strategy

Applying the HMGT 570 Week 10 SWOT framework (Daemmrich; HBS *SWOT Analysis I*) and the Ginter strategic-management process, this chapter converts the six-workstream situational analysis into a decision-grade SWOT and an action-oriented TOWS matrix. The discipline of TOWS is that it forces strengths and weaknesses (internal) to be *matched against* opportunities and threats (external), producing four strategy postures rather than a static list: **SO** (offensive — use strengths to seize opportunities), **ST** (defensive — use strengths to blunt threats), **WO** (improvement — fix weaknesses to capture opportunities), and **WT** (survival — minimize weaknesses while avoiding threats).

### The strategic picture in one paragraph

Redlands Community Hospital (RCH) is a paradox: it owns a genuinely VRIO-defensible asset — a dominant local ED front door (61,472 visits, ~57-59% home-ZIP share) attached to a 120-year independent brand and a top-100 ortho/spine franchise — while its acute core erodes (discharges -31.1% to 9,604; births -38.2% to 1,336; FY2024 operating loss ~$8.6M) on a balance sheet that funds only ~51 days of operations. The external field is, on net, favorable to vertical integration but on a regulatory knife's edge: ~5,100 recapturable discharges (~$89M ceiling), ~22,000 capturable commercial lives against just 1,405 on RCH's own plan, ~320 aggregatable independent PCPs, and a 2026 SB351 hospital carve-out that advantages RCH against payer-owned Optum and PE roll-ups. The strategic logic of TOWS, therefore, is to **harvest the ED/ortho/ambulatory strengths to fund a capital-light, prevention-first forward integration** (Ginter forward vertical integration + related diversification via cooperation-before-purchase) **before** inpatient decay and balance-sheet erosion narrow the option set toward a distressed sale.

### TOWS Matrix

| | **Opportunities (O)** — recapturable ~5,100 discharges/$89M; ~320 independent PCPs (CIN 80-150k lives); ~22,000 capturable commercial lives; Pass-corridor whitespace; IE chronic-disease VBC fuel; CalAIM rails; ambulatory migration | **Threats (T)** — Optum/Beaver payer-owned gatekeeper + CPOM; LLU expanding into Redlands (~28% leak); shrinking independent pool; -6.0%/yr inpatient decay; Kaiser closed-network lock (~11%); AB1415/OHCA review clock; FQHC/retail entrants; 2030 seismic capex |
|---|---|---|
| **Strengths (S)** — dominant ED front door; ortho/spine franchise; 120-yr brand + #3 employer + $58M community benefit; 56.6% occupancy headroom; outpatient = 58% of net patient rev; SB351 hospital carve-out; Yucaipa feeder dominance | **SO (Offensive).** Convert ED dominance into retained admissions (close half the ~18-pt conversion gap → 42% core share = +803 discharges/+$14.0M, no capex). Build the CIN nucleus around Yucaipa by signing CAMG and a now-independent RYMG first. Weaponize SB351 as a "stay independent, stay local" recruiting asset. Fund an ASC/RPM build from outpatient strength rather than beds. | **ST (Defensive).** Aggregate the ~320 independents *now* via CIN+MSO to neutralize Optum supplier power before the pool is absorbed. Compete on Porter focus/differentiation (elective ortho-spine, access), conceding trauma/peds to LLU via affiliation. Re-occupy the urgent-care front door Optum vacated and own the ASC channel. Treat recapture as defense against -6.0%/yr decay. |
| **Weaknesses (W)** — ~$8.6M operating loss, 6/14 negative years; ~51-day cushion; inpatient/OB decline; CMS 2-star vs. marketed 4-star + worse-than-national stroke mortality + Leapfrog non-participation; ED-to-IP conversion collapse (21.4%→10.1%); no owned PCP/pop-health base; sub-scale (6.7% system beds); CEO-comp optics | **WO (Improvement).** Fix the quality-credibility gap as Phase 0 (restore Leapfrog, remediate stroke mortality, reconcile the star claim) before any negotiation. Sequence the build cash-generative — harvest ortho/ambulatory and recapture first, defer Knox-Keene risk. Open with rung-1 direct-to-employer contracts (RCH's own plan → ESRI/RUSD) for zero-license lives. Make the explicit OB defend-or-contract decision. | **WT (Survival).** Don't chase the full 63.2% leak — anchor the board/lender narrative to the ~52% recapturable pool with a credible 42-46% band. Secure external capital (JV/MSO partner or philanthropic campaign on the $58M community-benefit story) before the window closes. Adopt a "lowest-compliant-rung" deal doctrine: start the AB1415 90-day clock early, stage deals below the CMIR trigger. Pre-empt the CEO-comp optics in capital materials. |

### Reading the matrix

The **SO quadrant is where Redlands Health wins** and should command the first wave of capital and management attention: the ED-to-inpatient conversion play is the single cheapest, highest-return move in the entire strategy ($14M against an $8.6M loss, achieved through protocols and on-call depth rather than capex), and the CAMG/RYMG signings are the time-sensitive moves that unlock everything downstream. The **WO quadrant is the gating prerequisite** — the CMS 2-star/4-star credibility gap and stroke-mortality flag silently discount every physician-recruitment, payer, and employer conversation, so quality remediation is Phase 0, not a parallel track. The **ST quadrant resolves the strategy's central tension**: RCH's two binding Porter forces (supplier power + rivalry) share one root cause — a sub-scale hospital whose physician feeder is being absorbed by a payer it cannot legally out-employ — and the single move that attacks both is the CIN, which converts the most-feared supplier into an owned asset. The **WT quadrant is the honesty discipline**: with a ~51-day cushion and 6-of-14 negative operating years, RCH cannot self-fund this build, so the survival posture is disciplined leakage framing, early external capital, and strict regulatory sequencing under the SB351/AB1415 regime. In Ginter terms, the integrated directional thrust is a **defender-to-analyzer/prospector pivot** executed through **cooperation-before-purchase** market entry — banking lives and recaptured volume at the lowest compliant rung before ever bearing full Knox-Keene insurance risk.

---

# 8. Strategic Options, Market Entry & Growth Horizons

## Strategic Options, Market Entry & Growth Horizons

### From diagnosis to direction

The five preceding workstreams converge on a single, uncomfortable conclusion: **Redlands Community Hospital (RCH) cannot defend its way to survival.** The acute core is shrinking (total discharges fell 31%, 13,946 in 2018 to 9,604 in 2024; newborns down 38% to 1,336), the hospital ran an **~$8.6M operating loss in FY2024** on a -2.1% margin, and net assets have eroded 28% from a 2017 peak of $79.8M to $57.5M — roughly **51 days of operating cushion** (`rch_financials_utilization.csv`). Meanwhile RCH loses **63.2% of its own core-market inpatients** (`rch_market_leakage_analysis.md`). In Ginter's terms, a *maintenance* strategy (status quo or enhancement) is off the table; the only question is which form of **expansion** — and at what risk and pace.

The answer the data forces is **forward vertical integration**. RCH's value chain (Ginter Ch. 8) leaks at exactly two layers: it owns a genuinely VRIO **pre-eminent ED front door** (61,472 visits in 2024, ~57-59% home-ZIP share) and a VRIO **ortho/spine franchise** (US News High Performing x4) at *point-of-service* — but owns **nothing defensible in pre-service** (no primary-care base) or **after-service** (no population-health infrastructure). Those two empty layers are precisely where the "Redlands Health" vision builds. Vertical integration here is internally justified, not merely market-opportunistic.

### Recommended directional strategy

**EXPANSION via forward vertical integration + related diversification + market development, with a disciplined CONTRACTION sub-strategy on sub-scale acute lines.** RCH integrates forward into owned/aligned primary care (the CIN) and after-service population health (care management, hospital-at-home, ultimately a health plan); diversifies into related ambulatory/surgical and risk-bearing businesses; develops the **San Gorgonio Pass** market; and *simultaneously* retrenches or makes an explicit defend-vs-harvest call on declining lines such as OB. Growth and contraction run in parallel — the hallmark of a portfolio managed for margin, not nostalgia.

### Recommended market-entry vehicle: cooperation before purchase

California's **Corporate Practice of Medicine** bar (B&P §2400) settles the build-vs-buy debate before it starts: RCH legally **cannot acquire physicians by employing them** (`california_regulatory_requirements.md`). The lowest-capital, lowest-friction, fastest vehicle is therefore **COOPERATION** — aggregating the corridor's **~320 independent PCPs** (defensible ~270-490 PCP-FTE) into an RCH-led **clinically integrated network** via affiliation and MSO agreements (`independent_provider_analysis.md`). Cooperation needs **no Knox-Keene license**, stays **sub-threshold for an OHCA/AB1415 market-impact review**, and exploits a closing window: **CAMG** was founded in 2024 explicitly to keep care local, and **RYMG just left Optum** — landing RYMG alone roughly doubles the PCP base and brings its own urgent care. **Internal DEVELOPMENT** funds the ASC, hospital-at-home, and digital-CIN backbone (capital follows demand: outpatient surgery is already 57.6% of the surgical mix). **PURCHASE/JV** is reserved for later, well-capitalized waves — RCH's 51-day cushion forbids a balance-sheet-funded acquisition spree.

### Recommended competitive strategy: focused differentiation

RCH commands only **~6.7% of the competitive ring's beds** and runs at **56.6% GAC occupancy** while LLUMC runs at **109%** and San Gorgonio Memorial at **27.5%** (`hcai_utilization_comparison.csv`). It cannot win on **cost leadership** (Kaiser's closed-network scale) or **breadth/acuity** (LLU and Arrowhead own Level I trauma, peds, quaternary care). Its winnable seam is **focused differentiation** (Porter): the *local, integrated, prevention-first, lower-total-cost* system for community-acuity needs across a defined geographic focus — Redlands → Yucaipa/Calimesa → the Pass. The differentiation rests on three pillars: the **ED-to-admission funnel**, the **ortho/spine ASC franchise**, and **independence itself** — SB351's hospital carve-out makes RCH the non-payer, non-PE home for physicians fleeing Optum, a position rivals legally cannot match.

**One non-negotiable Phase 0 caveat:** RCH cannot differentiate on quality while its public scorecard contradicts its marketing. Live **CMS 2/5 stars** (vs. the 4/5 RCH advertises), **stroke 30-day mortality "Worse than national,"** and **Leapfrog non-participation since Fall 2024** must be remediated first — every physician-recruitment, payer, and employer conversation is currently priced at a credibility discount.

### The three growth horizons

| Horizon | Ginter adaptive strategy | Entry vehicle | The core move | Quantified prize |
|---|---|---|---|---|
| **H1 — Stop the Leak (0-2 yr)** | Penetration + light forward integration; retrenchment on sub-scale lines | **Cooperation** (CIN affiliation + MSO); internal development (ASC/access) | Form the CIN; convert the ED moat into admissions; rung-1 direct-to-employer contracts | 36.8% → 42% core IP share ≈ **+$14.0M** net IP revenue; ED admit-conversion 10.1% → recovery |
| **H2 — Build the System (2-5 yr)** | Full forward integration + related diversification + market development | **Cooperation → purchase/JV** (friendly-PC + MSO; Pass-corridor sites); internal development (hospital-at-home/RPM) | Friendly-PC/MSO PC base; rung-2/3 shared-savings; San Gorgonio Pass expansion | 46-50% core share band ≈ **+$25-36M**; high-cost tier (~6-7k lives) shared-savings |
| **H3 — Own the Model (5-10 yr)** | Related diversification (provider-sponsored plan); completed integration; regional scale | **Purchase / internal development** (Knox-Keene plan); cooperation with capital partner | Restricted → full Knox-Keene; §1206(l) foundation; regional consolidation | 1,405 → ~22,000 capturable commercial lives (**15x**); CIN ceiling ~700,000 |

**H1 (0-2 yrs) — Stop the Leak.** Sequence everything behind **Phase 0 quality repair**. Sign the anchor CIN affiliations (CAMG, RYMG, Arrowhead Orthopaedics, the risk-bearing IPAs), building real clinical **and** financial integration *before* any joint payer contracting (or it is per-se antitrust). Convert the ED franchise into retained admissions — RCH already has the patient in the building but admits only ~10.1% of ED visits, down from 21.4% in 2018; closing half the ~18-point ED-to-IP gap is the cheapest path to +$14M. Launch zero-licensure rung-1 contracts (ESRI's 4,890 self-funded lives, RUSD, the in-house 1,405-life plan as proof-of-concept). Make the explicit OB decision. Start the **AB1415 90-day clock** the day any deal is board-credible, staged to avoid a bundled CMIR.

**H2 (2-5 yrs) — Build the System.** Stand up the CPOM-compliant primary-care vehicle (friendly-PC + MSO, building toward a §1206(l) foundation), climb the risk ladder into shared-savings/global risk (inheriting RBO infrastructure from the IPAs rather than building solvency from scratch), and execute **market development into the San Gorgonio Pass** — the corridor's clearest whitespace, served only by one fragile 79-bed district hospital at 27.5% occupancy and not yet entrenched by LLU or Kaiser. Build **hospital-at-home and RPM** as the after-service layer aimed at the ~5-6% high-cost tier that drives ~50% of spend. Capital flows to ambulatory, not beds — and looming HCAI seismic capex should *force* that rationalization.

**H3 (5-10 yrs) — Own the Model.** Only after the CIN demonstrably manages medical cost: climb the **Knox-Keene ladder** (Restricted → full-service + reserves) to operate the Redlands Health **provider-sponsored plan**, capturing the full margin of the lives it serves. Complete the §1206(l) foundation. Scale to the corridor's addressable ceiling. Hold focused-differentiation discipline at scale — remain the local, integrated, prevention-first alternative, never a me-too giant.

### What Redlands Health could grow into by ~2035

Picture the corridor a decade out. A resident of Yucaipa wakes with chest tightness and is seen the same day at a **Redlands Health primary-care site** — one of dozens stitched together from CAMG, RYMG, and the independents who chose to stay free of Optum. Her cardiologist, her labs, her imaging, and her record all live inside one network; when she needs a knee replaced, it happens at a **Redlands Health ambulatory surgery center** built on the ortho franchise that was always RCH's crown jewel, and her recovery is monitored at home by an **RPM-and-hospital-at-home team** instead of a hospital bed. Across the **San Gorgonio Pass** — once served by a single fragile 79-bed district hospital — Redlands Health access points now anchor the region's fastest-growing population lane. The **63.2% of inpatients who used to leak to Loma Linda and Kaiser** increasingly stay home, because home now offers an integrated system, not just a 211-bed building. The ED that was always RCH's front door has become the **front door of a health system**, funneling lives into a network that keeps them well rather than waiting for them to get sick. And the lives themselves — once 1,405 on a tiny in-house plan — now number in the tens of thousands, many of them covered by **Redlands Health's own prevention-first health plan**, where every dollar saved by keeping the Inland Empire's diabetic, hypertensive, aging population healthy flows back into keeping them healthier still. RCH the standalone hospital, running an $8.6M loss on a shrinking inpatient core, will have become **Redlands Health: the independent, prevention-first regional system that out-cared the giants it could never out-scale.**

---

# 8A. Acute Service-Line Market Entry & Reclaim Roadmap

*Added as a follow-on to the engagement, in response to: "include service lines that are potential market entries for an acute hospital, and a roadmap to reclaim the area and grow so we don't get acquired or forced to sell." Full detail in `service_line_market_entry.md` and `service_line_scorecard.csv` (23 candidate lines x 8 weighted criteria). This is the service-line expression of the Chapter 8 directional strategy.*

**The core insight.** RCH does not have an access problem; it has a **conversion-and-retention problem at the service-line level.** It wins the front door (~57-59% home-ZIP ED share on 61,472 visits) but keeps only 36.8% of its core inpatient market. The leak splits into a **structurally-locked tier** (Level I trauma, complex pediatrics, quaternary/academic, Kaiser closed-network — ~two-thirds to 70% of the leak) that RCH should not chase, and a **community-acuity tier** (~2,500-3,100 recapturable discharges, est) the right service lines can win back. The gap is not geography — these patients are already in RCH's ED — it is service-line depth, on-call specialist coverage, and the credibility to keep them.

**Scoring.** Each candidate line was scored 1-5 on eight weighted criteria — market need (16%), leakage-recapture (18%), competitive whitespace (14%), capital favorability (12%), regulatory feasibility (12%), reimbursement/payer mix (10%), VRIO/vision fit (12%), time-to-stand-up (6%) — producing a 0-100 weighted score. Tier (H1/H2/H3) is a separate sequencing judgment under the concurrent-initiative cap.

**Data limitation (stated up front).** The HCAI patient-origin file has no DRG/service-line detail; the restricted HCAI Patient Discharge Data (PDD) would let the team compute leakage by DRG family and convert the ~two-thirds tertiary-split *assumption* into a measured number. Until then, service-line targeting reasons from RCH's published lines, competitor capability, IE epidemiology, and capacity data.

## H1 shortlist (0-2 yrs) — stop the leak

| Rank | Service line | Score | Partner/group | Why H1 |
|---:|---|---:|---|---|
| 1 | Ortho/spine Center of Excellence + total-joint + ortho ASC | 91 | Arrowhead Orthopaedics | Monetizes the #1 VRIO franchise; ASC serves daytime workers & any payer; lowest execution risk |
| 2 | Primary Stroke Center + neuro | 86 | LLUMC Adult (thrombectomy backstop) | Fixes a live quality liability AND stops EMS routing to LLU — quality fix + recapture in one |
| 3 | Urgent care / convenient-access front door | 86 | CIN / RYMG | Owns the front door; fills Optum's 2024 retreat; feeds CIN attribution |
| 4 | Observation / clinical-decision unit | 85 | Internal (ED moat) | Near-zero-capex ED-moat conversion at 56.6% occupancy; transfer-prevention |
| 5 | Occupational health + employer near-/on-site clinics | 85 | Direct-to-employer (ESRI/RUSD/Amazon) | Monetizes the ~33,000 daytime in-commuters; payer-agnostic B2B |
| 6 | GI / endoscopy + ASC | 84 | Inland Gastroenterology | Margin-positive outpatient; recaptures elective endoscopy leaking to ASCs |
| 7 | Endocrinology / diabetes & cardiometabolic prevention | 83 | CIN PCPs + endo; payer VBC | The prevention-first/CIN savings engine; bullseye for IE chronic-disease burden |
| 8 | General surgery / urology / ENT / bariatrics via ASC | 81 | Independent surgeons via CIN | Rides the outpatient surgery-mix shift; bariatrics maps to 36.5% obesity |
| 9 | Interventional cardiology (cath lab) + Chest-Pain/STEMI | 78 | On-campus cardiology; Kaiser/LLU CABG backup | The capital-heavy exception — biggest case-mix lift & cardiac recapture |
| 10 | Advanced imaging + interventional radiology | 75 | Owned/JV vs. RadNet | Enabling infrastructure for stroke/cardiac; outpatient imaging for daytime workers |

All gated behind the **Phase 0 quality fix** and sequenced within H1 (not launched simultaneously).

## H2 (2-5 yrs) — depth & the after-service layer
Vascular surgery (74), wound care + hyperbarics (76), pulmonology/sleep (74), pain management (73), oncology deepening (70; rad-onc linac via JV/defer), geriatrics/palliative (77), hospital-at-home + post-acute (77), behavioral health — SUD/MAT + crisis + geri-psych (66; affiliate LLU's inpatient psych, don't compete it), women's health defend-or-harvest OB + grow gyn/urogyn/breast (68), nephrology/CKD-in-CIN (66; concede chronic dialysis chairs).

## H3 (5-10 yrs / conditional) — own the model
Comprehensive Stroke / neuro-interventional thrombectomy (only if volume + LLU economics justify graduating from Primary), owned radiation oncology (linac), the provider-sponsored health plan (Restricted -> full Knox-Keene), and Pass-corridor market development — each an earned option, not a commitment.

## What NOT to build (concede by partnership)
**Level I/II trauma** (LLUMC + Arrowhead, who run at 109%/86%), **complex pediatrics** (LLU Children's monopoly), **quaternary/transplant/complex CV surgery** (LLUMC academic franchise), and **owning chronic outpatient dialysis chairs** (DaVita/Fresenius dominance). The two acute partnerships — **LLUMC Adult** and **Kaiser Fontana/Moreno Valley** — absorb the unwinnable tiers so RCH's capital and management bandwidth go entirely into the recapturable community-acuity lines. Conceding trauma is the discipline that makes focused differentiation financeable.

## Top 3 leakage-recapture opportunities
1. **The ED-to-inpatient retention chain** (observation unit + cardiac cath/STEMI + Stroke Center) — keep the community-acuity admissions already presenting in RCH's ED; largest recapturable pool, near-zero new market access.
2. **Elective surgery leaking to freestanding ASCs** (ortho/spine + GI + general/uro/ENT) — recapture margin on the documented outpatient surgery shift (3,871 > 2,854).
3. **Cardiac volume routing to LLU** for want of an interventional program — a cath lab + Chest-Pain Center recaptures it and lifts case-mix.

**How the program defends independence:** a hospital that has recaptured its leak, owns its front door, anchors a physician network the giants cannot, and manages the region's chronic disease at risk is not a distressed-sale candidate. That is the entire point of the sequence.

---

# 9. Financial & Value-Creation Case

Financial and Value-Creation Case for Redlands Health. Planning estimates, not actuarial; sources cited inline. RCH ran an 8.6M FY2024 operating loss (407.1M revenue versus 415.7M expenses), the sixth negative-operating year of fourteen; net assets fell from a 79.8M peak in 2017 to 57.5M in 2024, about 51 days of operating cushion; total discharges fell 13,946 to 9,604, down 31 percent since 2018, and births fell 38 percent (rch_financials_utilization.csv; rch_hospital_data.md). At the observed minus 6 percent per year discharge CAGR the base decays toward about 7,970 discharges by 2027, so the spend below is as much defense as growth.

Four value pools. (1) Inpatient recapture is the highest-contribution lever: the core six-ZIP draw area generates 15,513 discharges but RCH keeps only 5,712, a 36.8 percent share and 63.2 percent leakage (rch_market_leakage_analysis.md). At 167,573,733 over 9,604 equals 17,448 net IP revenue per discharge, lifting core share to 42, 46, and 50 percent yields plus 803, plus 1,424, and plus 2,044 incremental discharges worth plus 14.0M, plus 24.8M, and plus 35.7M gross net IP revenue. Do not chase the full leak: about 48 percent is structurally locked (Kaiser closed network about 11 percent, plus tertiary, peds, and trauma routed to Loma Linda about 28 percent and Arrowhead), so the realistically recapturable community-acuity pool is about 5,108 discharges, an 89M ceiling. The cheapest path is converting RCH's dominant ED (about 55 to 59 percent home-ZIP share) into retained admissions, closing the roughly 18-point ED-to-IP gap at 56.6 percent occupancy with no new tower. (2) Ambulatory and ASC: outpatient surgeries (3,871) now exceed inpatient (2,854), up 17.3 percent in two years, and net outpatient revenue (232.5M) outweighs net inpatient (167.6M); the proforma ASC line of 2,000 cases at 4,500 yields about 9.0M revenue and 3.1M contribution. (3) CIN shared savings, no license: a first-wave clinically integrated network of 80,000 to 150,000 lives over an estimated 528M to 990M total cost of care, where the high-cost 5 percent drive about 50 percent of spend, returns about 10.6M to 19.8M per year to RCH at a 4 percent savings and 50-50 split. (4) Owned at-risk plan, deferred: scaling RCH's 1,405 lives toward about 22,000 capturable commercial lives yields about 2.8M Year-1 contribution on 7,000 lives at proforma defaults, held as rung 4.

Value bridge, annual contribution to operating income, planning estimate. Start, FY2024 operating result, minus 8.6M (rch_financials_utilization.csv). Plus inpatient recapture to 46 percent core share, 1,424 discharges at 17,448 each, plus 8.7M (rch_market_leakage_analysis.md). Plus ASC line, 2,000 cases, plus 3.1M (site proforma). Plus CIN shared savings, mid-case about 115k lives, plus 15.0M (independent_provider_analysis.md). Plus owned plan, Year 1, 7k lives, plus 2.8M (site proforma). Minus CIN and care-management run overhead, 8M to 12M. Equals steady-state operating swing of plus 9M to plus 13M above today. The bridge is conservative on inpatient (46 percent, not 50 percent) and loads the biggest contribution onto the no-license CIN rung; the cheapest rung carries the most value, which makes the program financeable.

Investment, 60M to 110M, phased: CIN and MSO plus care-management IT 8M to 15M (Year 0-1); aligned primary care and 1206(l) foundation 20M to 40M (Year 1-4); ASC capex 15M to 25M (Year 1-3); Knox-Keene reserves 15M to 30M, deferred to rung 4 (Year 4 plus); working capital and J-curve ramp 10M to 20M (Year 0-3).

Return thesis and payback. Self-funding by sequence: the no-license CIN rung (18M to 35M, Phase 0-1) earns 10.6M to 19.8M per year, payback about 2 to 3 years on its slice, funding the heavier spend; ED-to-IP recapture lands 14M to 25M against an existing fixed-cost base at 56.6 percent occupancy; blended payback about 4 to 6 years, the early rung positive sooner, mirroring the J-curve already in the site proforma.

Honest counterweight. The thesis depends on three things RCH lacks: external capital (about 51 days cushion and 6 of 14 negative years mean a JV or managed-services partner, a philanthropic campaign on the 120-year brand and about 58.1M community benefit, or asset monetization); quality credibility (live CMS 2 of 5 versus the marketed 4 of 5, stroke mortality worse than national, Leapfrog non-participation since Fall 2024 (rch_hospital_data.md), fixed as Phase 0); and sequencing discipline (CPOM, the AB1415 and OHCA 90-day clock, and the Knox-Keene ladder demand lowest-compliant-rung moves or the payback breaks). Get these right and the math holds; get them wrong and minus 6 percent per year decay erases the opportunity first.

---

# 10. Recommendations & Roadmap

This chapter converts the diagnosis and value case into a committed program of action. It is organized into five parts: the twelve recommendations, the first-90-days action list, the risk register with mitigations, the KPI dashboard, and the closing vision.

## 10.1 Recommendations

1. **Green-light Horizon 1 ONLY as a committed program** (CIN formation + transfer-prevention + rung-1 direct-to-employer + Phase 0 quality fix). Explicitly classify H2/H3 (friendly-PC scale-up, §1206(l) foundation, global-risk Knox-Keene, owned plan) as conditional options to be re-approved on evidence — not a pre-committed 10-year roadmap.
2. **Make the Phase 0 quality remediation a hard stop/go gate:** re-enter Leapfrog, deploy a stroke 30-day-mortality remediation plan, and immediately reconcile the public 2-star-live vs. 4-star-marketed claim (a standalone integrity/governance risk). No term sheet with any physician group is signed until this is underway.
3. **Make external capital a precondition of program start.** Pursue a risk-enablement JV / managed-services partner that brings the CIN/MSO/care-management platform turnkey, plus a philanthropic capital campaign leveraging the 120-year brand and ~$58.1M community-benefit narrative. Do NOT plan to balance-sheet-fund this; re-underwrite the entire thesis on audited unrestricted days-cash-on-hand, not 990 net assets.
4. **Re-underwrite all recapture economics:** use ONE discharge denominator (~15,429 core), cap the headline at a 40-42% share target (+480 to +788 discharges), report results in contribution margin (~+$2-5.5M) not gross revenue, and do not stack ED-lever dollars on share-recapture dollars.
5. **Before booking ANY transfer-prevention upside,** decompose the ED-to-IP gap with actual case-mix/DRG data to confirm the leaked admissions are community-acuity (recapturable) rather than tertiary/trauma routed legitimately to LLU's Level I.
6. **Fund the organizational-readiness workstream as line items:** a named CEO sponsor + guiding coalition (Kotter), a hired VP Population Health/VBC, and a CIN executive director. Cap concurrent net-new initiatives in any 18-month window — do not run ASC build, CIN stand-up, friendly-PC formation, and quality remediation all at once.
7. **Build genuine clinical AND financial integration** (shared EHR, care pathways, shared risk) across the CIN BEFORE any joint payer contracting, with California health-care counsel pre-clearing the integration design — and budget the shared-EHR/interoperability backbone explicitly in the CIN/IT line, recognizing it precedes revenue (RYMG notably left Epic).
8. **Treat CAMG and RYMG signings as binary risks** with named owners and fallback scenarios; model the first-wave lives base WITHOUT RYMG to prove the program still works if the most important anchor walks or is out-bid by Optum/LLU. Win physicians on deliverable economics (VBC infrastructure, local referral economics, ortho/spine franchise), not on SB351 alone — which restrains PE roll-ups, not payer-owned Optum.
9. **Split the CIN lives narrative:** present 80-150k as an aggregation ceiling already attributed to incumbent payers, and a low-single-digit-thousands day-one shared-savings slice ramping to 30-60k over 3-5 years; model shared savings on a J-curve (~$0 net years 1-3, steady-state earn-out years 4+).
10. **Make an explicit, board-minuted OB defend-or-harvest decision** rather than allowing passive erosion — recognizing that harvesting forfeits the maternity first-touch that feeds family commercial lives into the CIN.
11. **Treat AB1415/OHCA as a master clock with real teeth:** assume at least one anchor deal draws a CMIR and slips 6-12 months in the base-case timeline; start the 90-day notice the day a deal is board-credible; pre-wire OHCA and the AG with the community-benefit narrative, but do not assume it converts review into a rubber stamp.
12. **Right-size H3 ambition:** hold rungs 1-3 (direct-to-employer, narrow network, CIN/ACO shared savings) as the durable position capturing most upside with light/no licensure; require a separate future capital case for any owned-plan decision.

## 10.2 First 90 Days — Action List

- Convene the board and incoming CEO to formally adopt the Horizon-1-only mandate and explicitly classify H2/H3 as conditional options; name the executive sponsor and guiding coalition (Kotter step 1-2).
- Launch the Phase 0 quality remediation as a stop/go gate: file to re-enter Leapfrog, stand up a stroke 30-day-mortality remediation team, and within 30 days reconcile/correct the public 2-star-live vs. 4-star-marketed claim across all RCH marketing.
- Commission a true-liquidity re-underwrite from audited financials (unrestricted days-cash-on-hand, bond covenants, DSH/340B exposure, 2030 seismic capital) to replace the 990 net-asset figure as the planning basis.
- Open conversations with 2-3 risk-enablement / managed-services partners and frame the philanthropic capital campaign — establish that external capital is secured (or credibly committed) before any deal closes.
- Pull RCH's ED-to-IP case-mix/DRG data to decompose the leaked-admissions gap into community-acuity (recapturable via transfer-prevention) vs. tertiary (not), before any recapture dollars are booked.
- Initiate exploratory, counsel-led discussions with CAMG and RYMG (and Arrowhead Orthopaedics / the IPAs), with a parallel lives model that excludes RYMG to test anchor-concentration risk.
- Engage California health-care counsel to design the CIN's clinical+financial integration so it is defensibly integrated before any joint contracting, and to map the AB1415/OHCA and AG (§5914-5925) timelines.
- Stand up rung-1 direct-to-employer outreach to ESRI and RUSD and scope converting RCH's own 1,405-life plan into the CIN proof-of-concept.
- Write the VP Population Health/VBC and CIN executive director job specs and begin recruitment (or fold these into the partner-platform decision).
- Bring an explicit OB defend-or-harvest decision memo to the board with the maternity-first-touch / CIN-lives tradeoff quantified.
- Define the H1 KPI dashboard and baseline every metric (core share, contribution margin, days-cash, quality scores, signed lives, J-curve burn) so progress is measured against committed numbers.

## 10.3 Risks & Mitigations

- **Execution / change-capacity failure (the fatal risk): a money-losing, sub-scale hospital with an incoming CEO and no VBC muscle cannot stand up a CIN, MSO, ASC, friendly-PC, and at-risk contracting concurrently — the single most common way transformations like this fail.** → Gate the whole program behind a funded organizational-readiness workstream: named CEO sponsor + guiding coalition, hired VP Population Health and CIN ED, and a turnkey risk-enablement/managed-services partner that brings the operating platform. Cap concurrent net-new initiatives per 18-month window. Make the Phase 0 quality fix a stop/go proof the org can execute.
- **J-curve / liquidity trap: 'self-funding by sequence' assumes shared-savings cash in years 2-3 that new CINs routinely do not deliver, while the ~51-day cushion is net assets (equity), not unrestricted cash.** → Re-underwrite on audited unrestricted days-cash-on-hand; make external/partner capital a precondition of start; model CIN savings on a 3-5 year J-curve (~$0 net years 1-3); fund the J-curve trough explicitly with the capital stack, not with assumed early earn-out.
- **Recapture over-claim: gross-revenue dollars on an inconsistent denominator overstate the prize; ~70% of the leak is structurally locked (Kaiser + LLU/Arrowhead tertiary/trauma/peds), and recaptured payer mix is Medi-Cal-skewed.** → Cap the board target at 40-42% core share (+480 to +788 discharges) on a single ~15,429 denominator; report contribution margin (~+$2-5.5M), not gross; validate community-acuity vs. tertiary with DRG/case-mix data before booking any upside; apply market decay to the recapture pool, not just to RCH's base.
- **Anchor concentration / physician-supply attrition: the lives model leans heavily on RYMG and CAMG; Optum keeps absorbing groups and can out-bid, buy anchors, or out-wait RCH.** → Model first-wave lives WITHOUT RYMG; treat each anchor as a binary risk with a named owner and fallback; lead recruitment with deliverable physician-income and infrastructure value gated on the Phase 0 quality fix; sign fast while the re-independence tailwind (CAMG/RYMG) is fresh.
- **Regulatory delay and double-gating: AB1415/OHCA now covers MSOs/new entities and can treat a sequenced series of related deals as a bundled CMIR; AG asset-transfer review (Corp Code §5914-5925) adds a second overlapping gate; success itself ratchets OHCA cost-target scrutiny.** → Build at least one 6-12 month CMIR slip into the base-case timeline; start the 90-day clock early and stage deals individually; engage CA health-care counsel to pre-clear CIN integration design; pre-wire OHCA and the AG with the community-benefit/'keep care local' narrative on every filing.
- **ED-lever double-count and structural misread: crediting a phantom 18-point ED-to-IP 'conversion gap' double-counts share-recapture volume; most leaked admissions may be legitimately tertiary.** → Reframe the lever as transfer-prevention + downstream referral capture; decompose the gap with case-mix data before booking dollars; never stack ED dollars on share-recapture dollars.
- **§1206(l) foundation contradiction: the foundation's 2/3-full-time and clinical-control requirements conflict with the independence pitch used to recruit the physicians; the research/education mission is a multi-year institutional build RCH lacks.** → Demote the foundation from 'destination' to a conditional year-7+ option; make the friendly-PC + MSO the actual durable operating model; only revisit a foundation if an aligned group organically crosses the 40-MD/10-specialty threshold.
- **Owned-plan over-reach: listing a full Knox-Keene plan as the endgame anchors the board on a destination the capital reality forbids and that routinely sinks well-capitalized systems.** → Label rung 4 a remote option requiring a separate future board capital case; hold rungs 1-3 as the durable position; bear global risk (Restricted Knox-Keene) only after multi-year demonstrated medical-cost management, inheriting RBO solvency from aggregated IPAs.
- **Stranded-cost, labor, and brand risk from contraction: right-sizing med-surg and an OB harvest at a unionized #3-employer community anchor carries labor, community, and political costs — and a botched OB closure poisons the 'keep care local' brand.** → Make an explicit, board-minuted defend-or-harvest OB decision; sequence and communicate any contraction with labor and community stakeholders; weigh OB's maternity first-touch value as a CIN family-lives feeder before any closure.
- **Medical-staff and governance friction: aggressively recruiting independents into a hospital-led CIN and steering referrals can trigger self-governing medical-staff resistance (B&P §2282.5) and exclusion/antitrust claims from physicians left out.** → Engage the medical staff early as partners in CIN design; ensure transparent, clinically-integrated inclusion criteria; route network design through counsel to defend against exclusion/antitrust exposure.
- **Governance optics on a capital raise: FY2024 CEO compensation (~$1.17M, ~14% of the operating loss) becomes the story that sinks a lender/donor conversation.** → Proactively contextualize executive compensation in lender/donor materials before it is raised externally; pair the raise with the community-benefit and turnaround narrative.

## 10.4 KPIs

- Core five-ZIP inpatient market share: baseline 36.9% → 40-42% target (single ~15,429-discharge denominator) [rch_market_share_leakage.csv]
- Incremental recaptured community-acuity discharges: +480 to +788, reported in CONTRIBUTION MARGIN (~+$2-5.5M), not gross revenue
- Unrestricted days-cash-on-hand (audited, NOT 990 net assets) — primary solvency guardrail through the J-curve
- CMS Overall Star Rating (2/5 → 3+/5), Leapfrog participation restored, stroke 30-day mortality returned to 'No different than national'
- Marketing-claim integrity: public quality claims reconciled to live CMS data (binary stop/go)
- Signed CIN physicians/PCP-FTE and ATTRIBUTED shared-savings lives (day-one VBC slice tracked separately from the 80-150k aggregation ceiling)
- Anchor signings: CAMG and RYMG status, with a lives model maintained both WITH and WITHOUT RYMG
- Rung-1 direct-to-employer lives committed (ESRI, RUSD, RCH own plan) — funnel from 22,000 TAM to a few thousand year-1-3 wins
- Transfer-prevention rate: community-acuity admissions retained vs. transferred out (after DRG validation)
- CIN J-curve burn vs. plan and external/partner capital drawn vs. committed
- Ambulatory/ASC outpatient surgical volume and contribution vs. inpatient (extending the 58% outpatient revenue base)
- Regulatory clock status: AB1415/OHCA notices filed, CMIR exposure, AG review timelines — with at least one 6-12 month slip assumed in base case
- Organizational readiness: VP Population Health and CIN ED hired; concurrent net-new initiatives held at or below the 18-month cap
- OB volume and the board-minuted defend-or-harvest decision status (births baseline 1,336)

## 10.5 Closing Vision

Picture Redlands in 2032. A family in Yucaipa has a Redlands Health primary-care doctor who is still independent — never sold to a payer — but now backed by the contracting muscle, care management, and shared data of an RCH-led network that kept care local when Optum and the academic giants were absorbing everything around it. When that family needs surgery, it happens down the road at a Redlands ambulatory center, not 40 minutes north; when a parent lands in the ED, they are admitted and recovered at RCH rather than transferred away; and when a chronic condition flares, a care team reaches them at home before it becomes a crisis. RCH is no longer a shrinking acute hospital waiting for a distressed-sale conversation — it is the trusted, prevention-first home for community-acuity care across the Pass corridor, financially stabilized by the volume it stopped leaking and the lives it now manages at risk. That future is reachable, but only on the honest path: win the quality credibility back first, prove the model at the lowest compliant rung with partner capital and a real management bench, earn each larger move rather than assume it, and let the foundation and the owned plan remain options that scale only after the network has proven it can manage cost. Redlands Health becomes the Inland Empire's proof that an independent community hospital can choose integration over absorption — and keep its city healthy, and cared for, close to home.

---

# Appendix A — Partner Review (How the Strategy Was Stress-Tested)

This appendix records the adversarial review the strategy was put through before the recommendations above were finalized. Three independent attacks — a market-realism review of the demand math, a regulatory-and-execution feasibility review, and a financial-realism review — were run against the draft. Their verdicts and line-item findings shaped the corrections now embedded in the Executive Summary and Chapter 10.

#### Market-realism attack on demand, recapture, and CIN-lives math.

**Verdict:** Direction sound, demand math over-claimed. The recapturable leakage pool is overstated 40 to 65 percent because structurally-locked volume is about 68 percent of the core leak per the source CSV, not about 48 percent. The per-discharge revenue denominator is inconsistent (9604 vs 11162), inflating recapture dollars about 16 percent. The ED conversion-gap is misread because RCH already admits about 58.6 percent of discharges via the ED. CIN first-wave lives are an un-sourced ceiling already attributed to incumbent payers. Keep the strategy but rebuild around a 40 to 42 percent band, reframe the ED lever as transfer-prevention, and split CIN ceiling-lives from day-one VBC lives.

- **[major] About 52 percent of core leakage is recapturable** — Source CSV shows structurally-locked volume is 6715 of 9801 or 68.5 percent, not 48 percent. Residual is 3086 including Dignity 530, netting a realistic 2500 to 3100, far below the claimed 5108.
  *Fix:* Rebuild the pool to about 2500 and anchor the board case to 40 to 42 percent.
- **[major] Share lift yields plus 14 to 35.7M** — The 17448 per discharge uses 9604 discharges but the share math uses 11162 from the same HCAI vintage; the consistent denominator near 15013 cuts every figure about 16 percent, and the 46 and 50 percent volumes exceed the realistic pool.
  *Fix:* Use one discharge basis near 15000 and cap the headline at 42 percent.
- **[major] Closing the ED-to-IP conversion gap yields plus 14M** — RCH already admits 5625 ED patients, about 58.6 percent of its 9604 discharges, so the 10.1 percent is a normal treat-and-release ratio, not a recoverable 18-point gap; crediting it separately double-counts the share-recapture volume.
  *Fix:* Reframe as transfer-prevention and downstream referral capture, and do not stack ED dollars on share-recapture dollars.
- **[major] First-wave CIN of 80k to 150k lives generates 10.6 to 19.8M shared savings** — This is an aggregation ceiling with about 75 percent resting on RYMG estimates; the lives are already attributed to incumbent payers and most are FFS or IPA-capitated, not in RCH shared-savings contracts day one.
  *Fix:* Split ceiling-lives from a single-digit-thousands day-one VBC slice and ramp savings over 3 to 5 years.
- **[minor] Independents will join to form an owned referral base** — Optum and LLU hold most high-margin commercial and MA attribution; RCH pitches infrastructure it lacks from a 51-day cash base with a live 2-star rating, and Optum or LLU can out-bid, buy anchors, or out-wait RCH.
  *Fix:* Add an anchor-defection scenario, lead with fast physician-income value, and gate term sheets on the Phase-0 quality fix.
- **[minor] About 22000 capturable commercial lives, a 15 to 20x runway** — A modeled employer-coverage pool, not committed lives; only ESRI and the 1405-life plan are concrete, and conversion needs a narrow network not yet built.
  *Fix:* Present 22000 as TAM with a conversion funnel to a few thousand year-1-3 wins.

*Overlooked risks:* Payer-mix quality of recaptured volume is unaddressed; the Medi-Cal-skewed residual overstates contribution margin.; Market decay is applied to RCH but not the recapture pool, so 42 percent of a smaller 2027 market yields fewer absolute discharges.; Harvesting sub-scale OB forfeits the maternity first-touch that feeds family commercial lives into the CIN.; Recapture is modeled statically while LLU expands physically into Redlands.; Self-funding by sequence needs shared-savings cash in years 2 to 3 that a slower ramp will not deliver against the 51-day cushion.; No sensitivity on physician-supply attrition as Optum keeps absorbing groups.

#### Regulatory & execution feasibility — a skeptical review-partner attack on whether a single money-losing, 211-bed independent can actually build and operate this multi-horizon structure inside California's regulatory regime, with the leadership, capital, IT, and change capacity it requires.

**Verdict:** The strategic LOGIC is sound and the sequencing instinct (lowest-compliant-rung, cooperation-before-purchase, CIN-first) is exactly right — it is the only legally coherent path in California. But the engagement materially understates EXECUTION risk and quietly assumes away the binding constraint, which is not market size or even capital — it is organizational change capacity and management bandwidth at an entity that is currently losing money, leaderless-in-transition (new CEO Jan 2026), has no population-health muscle, and is being asked to stand up a CIN, an MSO, an ASC program, a friendly-PC, an at-risk contracting function, and eventually a §1206(l) foundation and Knox-Keene plan — most of which it has never done. The plan reads as a sequence of correct individual moves with no honest accounting of the people, governance, and operational throughput needed to run them concurrently. I would green-light Horizon 1 (CIN + ED conversion + direct-to-employer + quality fix) as a genuinely defensible, capital-light program, but I would force the team to treat H2/H3 (foundation, Knox-Keene, owned plan) as OPTIONS to be earned, not a committed roadmap — and I would not let the board approve the program until the change-capacity and management-team gaps below are funded line items, not assumed.

- **[major] Horizons frame the §1206(l) medical foundation as the H2-into-H3 'destination' built over 3-6 years, and the friendly-PC+MSO as a stepping stone toward it.** — The §1206(l) bar is far higher than 'a real build' — it is 40+ physicians, 10+ board-certified specialties, ≥2/3 full-time, PLUS a genuine medical research AND health-education mission (california_regulatory_requirements.md §A). RCH today owns ZERO employed-equivalent physicians and runs only two safety-net clinics. The corridor's entire defensible independent base is ~270-490 PCP-FTE spread across ~38 separate groups (independent_provider_analysis.md §4), and the anchor targets (CAMG 13 PCPs, RYMG 30-45) are physician-OWNED and joined the network precisely to STAY independent — they will resist folding into a hospital-controlled foundation that the 2/3-full-time and clinical-control requirements imply. The research/education mission is not a checkbox; it requires standing institutional infrastructure RCH does not have. Calling the foundation the 'destination' implies inevitability the facts do not support; realistically it is a 7-10 year proposition that may never close because the very independence pitch used to recruit the doctors is in tension with the foundation's control structure.
  *Fix:* Demote the §1206(l) foundation from 'destination' to 'conditional option, year 7+.' Make the friendly-PC+MSO the actual long-term operating model, not a way-station — it is CPOM-compliant, preserves the 'stay independent' recruiting promise, and avoids the 2/3-full-time and research-mission traps. Stress-test the foundation thesis against the contradiction that you recruited these physicians on independence and would then ask them to surrender clinical control. Only revisit the foundation if/when a single aligned group organically crosses the 40-MD/10-specialty threshold.
- **[major] The program is 'self-funding by sequence,' with ~$60-110M phased investment and Knox-Keene reserves 'deferred to rung 4 only,' funded by shared savings and ED-to-IP recapture.** — The self-funding logic has a J-curve hole the FINANCE section half-admits and then waves away. The shared-savings estimate ($10.6-19.8M/yr) is gross network savings at 4% of TCOC with a 50/50 split — but that is theoretical steady-state earn-out AFTER multi-year care-management buildout, not year-1 cash; new CINs routinely lose money for 2-3 years before any shared-savings check clears, and many never hit a 4% MLR improvement. Meanwhile the ED-to-IP recapture (+$14-25M) assumes RCH can close half an 18-point conversion gap — but the gap may be structural (the leaked admissions are the higher-acuity/trauma/peds cases that legitimately route to LLU's Level I, exactly the ~48% the team itself calls 'structurally locked'), not a coordination failure RCH can simply protocol away. If the early rungs do NOT throw off the assumed cash, the entire 'cash before the heavy spend' thesis collapses onto a balance sheet with negative operating margin and only ~$57.5M of net assets — which is NOT $57.5M of deployable liquidity. Net assets is equity (total assets $228.0M minus $170.5M liabilities); the unrestricted, spendable cash is materially lower, and much of those net assets is tied up in PP&E and restricted/donor funds. The '51 days' figure flatters the position.
  *Fix:* Re-underwrite the return thesis on UNRESTRICTED days-cash-on-hand from the audited financials (not 990 net assets), and pressure-test what truly funds H1 if shared savings = $0 in years 1-3. Make external capital (JV/managed-services partner or philanthropic campaign) a PRECONDITION of program start, not a fallback. Separately decompose the ED-to-IP gap with actual case-mix/DRG data to prove the leaked admissions are community-acuity (recapturable) vs. tertiary (not) before booking ANY of the $14-25M; if even half the gap is structural, the cheapest recapture lever is far smaller than claimed.
- **[fatal] Across all five workstreams: that a single independent 211-bed hospital can execute a four-horizon, multi-entity transformation — CIN, MSO, ASCs, friendly-PC, hospital-at-home, direct-contracting, foundation, Knox-Keene — over 2026-2035.** — This is the fatal gap the materials never address: CHANGE CAPACITY and MANAGEMENT BANDWIDTH (Kotter). The strategy implicitly assumes RCH has the leadership team, governance maturity, and operational throughput to stand up a half-dozen net-new business lines it has never run. The evidence says otherwise: (1) a NEW CEO arrives Jan 2026 mid-strategy-refresh — Kotter's 'guiding coalition' and 'sense of urgency' steps are unbuilt and leadership continuity is unproven; (2) the hospital cannot even maintain quality-signal discipline (CMS 2/5 live while marketing 4/5, Leapfrog non-participation, stroke mortality worse-than-national) — a basic operational-governance failure that directly predicts difficulty running far more complex new ventures; (3) there is no owned population-health, care-management, or VBC contracting competency anywhere in the org today; (4) each new entity (CIN, MSO, friendly-PC, ASC JV) needs its own governance, leadership, legal structuring, and management attention, competing for the same scarce executive bandwidth while the core hospital is losing money and faces a 2030 seismic capital mandate. A turnaround AND a build-out, concurrently, at a sub-scale independent, is the single most common way transformations like this fail.
  *Fix:* Add an explicit 'organizational readiness / change-capacity' workstream and gate the entire program behind it. Concretely: (a) sequence a Kotter-style Phase 0 that secures the new CEO's committed sponsorship and a named guiding coalition BEFORE any deal; (b) hire or contract-in the missing competencies (a VP of Population Health/VBC, a CIN executive director, MSO operating leadership) as a funded line item — do not assume existing staff can absorb this; (c) strongly favor a managed-services or JV partner that BRINGS the CIN/MSO/care-management operating platform turnkey (e.g., a risk-enablement partner), converting an execution-capacity problem into a partnering decision; (d) cap the number of concurrent new initiatives in any 18-month window — explicitly, do NOT run ASC build, CIN stand-up, friendly-PC formation, and quality remediation all at once; (e) make 'fix the quality-credibility gap' a true stop/go gate, since failure there proves the org cannot execute the harder steps.
- **[major] Cooperation-before-purchase lets RCH 'stay sub-threshold' on OHCA/AB1415 and avoid CMIR by staging deals one at a time; the 90-day clock is treated as a manageable 'master clock.'** — Two execution risks are underweighted. First, AB1415/OHCA (effective 1/1/2026) was EXPANDED to cover MSOs and newly-created entities (california_regulatory_requirements.md §D) — exactly the structures RCH must create. Regulators reviewing a sequenced series of related affiliations from the same hospital can and do treat them as a coordinated course of conduct ('a bundled CMIR') regardless of one-at-a-time paperwork; the staging tactic is not a reliable shield and a single CMIR can delay a closing by many months. Second, the CIN antitrust requirement is a real execution trap: the network may only jointly contract with payers if it is GENUINELY clinically AND financially integrated FIRST (shared EHR, care pathways, shared risk) — otherwise joint negotiation is per-se price-fixing (california_regulatory_requirements.md §C). Building real integration across ~38 independent groups on disparate EHRs, before any contracting revenue arrives, is slow, expensive, and is the precise point where the 'cash before heavy spend' timeline breaks.
  *Fix:* Build the OHCA/CMIR delay into the base-case timeline (assume at least one anchor deal draws a CMIR and slips 6-12 months) rather than treating sub-threshold staging as a clean avoidance. Engage California health-care counsel to pre-clear the integration design so the CIN is defensibly integrated before any joint contracting — and budget the shared-EHR/care-pathway integration cost explicitly in the $8-15M CIN/IT line, recognizing it precedes revenue. Pre-wire OHCA and the AG with the community-benefit/'keep care local' narrative on every filing, as the workstream recommends, but do not assume it converts review into a rubber stamp.
- **[minor] SB351's hospital carve-out is a durable recruiting 'weapon' that lets RCH win the ~320 independent PCPs against payer-owned Optum/Beaver.** — The carve-out is real but the team overstates it as a decisive advantage. SB351 restricts PE/hedge-fund clinical control; it does NOT restrain Optum/UnitedHealth, which is a payer-owned integrated entity, not a PE roll-up — so the law does little to blunt RCH's actual #1 rival for physicians. More importantly, recruiting physicians is not a legal exercise, it is an economic and operational one: Optum can outbid on income guarantees, capital, EHR, and care-management infrastructure that a money-losing 211-bed hospital cannot match. The independent pool is also finite and shrinking (Optum already absorbed Beaver, PrimeCare, IFMG), so the 'first-wave 80k-150k lives' depends on landing CAMG AND RYMG AND the IPAs essentially on schedule — a brittle, sequential dependency. If RYMG (the bloc that 'roughly doubles the base') re-affiliates elsewhere or stays standalone, the lives model loses its anchor.
  *Fix:* Reframe SB351 as a useful-but-narrow positioning point, not a moat — the carve-out helps against PE entrants, not against payer-owned Optum. Win physicians on what RCH can actually deliver: turnkey VBC/contracting infrastructure, local referral economics, and the ortho/spine franchise. Treat CAMG and RYMG signings as binary risks with named owners and fallback scenarios, and model the lives base WITHOUT RYMG to prove the program still works if the single most important anchor walks.
- **[minor] The four-rung Knox-Keene ladder lets RCH 'monetize lives progressively' and the owned health plan (rung 4) is a credible H3 endgame deferred only to 2031-2035.** — The ladder logic is correct, but the materials treat the owned-plan endgame as a natural extension when it is a category change in risk and capital that a hospital with this balance sheet should probably never reach. A full-service Knox-Keene plan requires tangible-net-equity reserves, TPA infrastructure, network-adequacy filings, and ongoing solvency oversight (DMHC) — the heaviest lift in all of healthcare, routinely fatal even to well-capitalized systems. Listing it in the vision risks anchoring the board on a destination that the capital reality forbids and that adds nothing to the near-term thesis. The 1-PCP-per-2,000 network-adequacy standard (a hard, enforced, annually-reported rule) further ties the plan's viability back to a physician base RCH does not yet control.
  *Fix:* Explicitly label rung 4 (owned plan) as a remote OPTION, not a planned endgame, and remove the implication that the strategy is incomplete without it. The defensible, durable position is rungs 1-3 (direct-to-employer, narrow network, CIN/ACO shared-savings) — which capture most of the upside with light/no licensure. Bear global risk (Restricted Knox-Keene) ONLY after the CIN has demonstrably managed medical cost for multiple years, and inherit RBO solvency infrastructure from the aggregated IPAs rather than building it. Owning a plan should require a separate, future board decision with its own capital case.

*Overlooked risks:* New-CEO transition risk (Jan 2026) is the single biggest unaddressed execution variable: a 10-year transformation requires sustained executive sponsorship and a stable guiding coalition, and the strategy is silent on whether the incoming CEO owns this thesis or arrives with a different agenda. The whole roadmap is hostage to leadership continuity the materials never test.; Medical-staff and board governance friction: a self-governing, peer-reviewed medical staff governs credentialing and clinical quality (B&P §2282.5). Aggressively recruiting independent PCPs into a hospital-led CIN, standing up a friendly-PC, and steering referrals can trigger medical-staff political resistance and even antitrust/exclusion claims from physicians left out of the network — an internal-politics risk distinct from the external regulatory one.; IT/EHR integration is treated as a line item but is a make-or-break operational dependency: a CIN spanning ~38 independent groups on heterogeneous EHRs (RYMG notably LEFT Epic on exiting Optum) cannot demonstrate the clinical integration that legitimizes joint contracting without a real, expensive interoperability and data-aggregation backbone. This is where VBC programs most often stall operationally.; Stranded-cost / contraction execution: the plan calls for right-sizing med-surg beds and a defend-or-harvest OB decision (births -38% to 1,336), but downsizing acute capacity at a unionized, community-anchor, #3-employer hospital carries labor, community, and political costs the materials don't size — and a botched OB closure can poison the 'keep care local' brand the whole CIN pitch depends on.; Counterparty concentration: the lives model leans heavily on RYMG ('roughly doubles the base') and CAMG. Two physician-owned groups, recently independent, are thin reeds to hang an 80-150k-life network on; their own viability, succession, and willingness to cede control to a hospital are unmodeled.; Regulatory-cost creep over a 10-year horizon: OHCA cost-growth targets ratchet down and apply to larger systems as RCH scales — success itself increases regulatory drag, so the later horizons get HARDER to execute, not easier, the opposite of the usual scale-economies assumption.; AG asset-transfer review (Corp Code §5914-5925) on any NFP control change adds a second, independent approval gate (public meeting, conditions) on top of OHCA — meaning later JV/purchase moves face TWO regulators with overlapping timelines, compounding delay risk on exactly the capital-raising transactions the thesis depends on.

#### FINANCIAL REALISM

**Verdict:** Direction sound; financial plan not investment-grade. Value bridge counts gross revenue as cash; cushion is net assets not cash; CIN savings assume a mature rate with no J-curve.

- **[fatal] Recapture revenue self-funds the build.** — It is gross revenue at 17,448 per discharge, not contribution margin; real cash is far smaller and double-counts ASC revenue.
  *Fix:* Rebuild on contribution margin; reconcile the discharge count; use NPV not payback.
- **[fatal] The 60 to 110M program is fundable and self-funds by sequence.** — The 51-day cushion is net assets not cash, no capital source is named, the J-curve trough is unplotted, and an owned plan can sink a small system.
  *Fix:* Sourced capital stack plus covenant-aware J-curve bridge; gate any plan license behind audited CIN cost management.

*Overlooked risks:* Bond covenants, DSH/340B erosion, the 2030 seismic mandate, and CAMG/RYMG concentration are unmodeled.

---

# Appendix B — Data Sources & Method

This analysis was built on public and official data sources, supplemented by the project data files maintained in this engagement folder.

**Primary sources:**

- **CMS Care Compare / Provider Data Catalog (PDC)** — quality measures, star ratings, mortality and readmission outcomes.
- **California Department of Health Care Access and Information (HCAI)** — Annual Utilization Report (discharges, ED visits, surgeries, occupancy, ALOS, net patient revenue); Patient Origin / Market Share Pivot Profile, CY2024 (ZIP-level inpatient and ED share, leakage).
- **IRS Form 990** (via ProPublica Nonprofit Explorer) — 14-year financial trajectory (revenue, expenses, operating margin, net assets, executive compensation), EIN 95-1643347.
- **DOL Form 5500 / Schedule A** (EFAST2) — employer health-plan participant counts and carrier/self-funded status.
- **CMS NPPES NPI Registry** — independent physician/provider census for the CIN aggregation analysis.
- **City of Redlands ACFR FY2024-25** — top-employer counts and city employment base.
- **Project data files in this folder** — the parsed, analyst-prepared CSV and Markdown files (e.g., `rch_market_share_leakage.csv`, `rch_market_leakage_analysis.md`, `rch_hospital_data.md`, `rch_financials_utilization.csv`, `rch_quality_scores.csv`, `independent_provider_analysis.md`, `california_regulatory_requirements.md`, `health_plans_form5500.md`, `competitors.md`, `hcai_utilization_comparison.csv`, and related files).

**Key caveats:**

- **CMS 2-star vs. marketing 4-star:** RCH's live CMS Overall Star Rating is 2/5 while its public marketing claims 4/5. This discrepancy is treated as a material integrity/governance flag, not a data error to be averaged away.
- **No service-line / DRG leakage detail:** the HCAI patient-origin file reports aggregate inpatient and ED share by ZIP, not by service line or DRG. The community-acuity vs. tertiary split of the leak is therefore an analyst assumption, flagged as an estimate, and must be validated with actual case-mix/DRG data before any recapture upside is booked.
- **Modeled lives / take-up estimates:** the covered-lives funnel (jobs → commercial lives → capturable → direct-contract wedge) rests on modeled take-up and Kaiser-share assumptions, exposed in sensitivity grids. These are planning figures, not committed lives.
- **Verify Form 990 against source PDFs:** the financial series is drawn from aggregated 990 data and should be reconciled to the original filed PDFs before use in any capital-raising materials.
- **California-only leakage:** the HCAI market-share analysis captures California hospital destinations only; out-of-state or non-reporting destinations are not represented.

**Method:** this report was produced via a multi-agent consulting-style workflow (six discovery workstreams, a strategy table, an adversarial partner review, and a managing-partner synthesis).